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Abstract:  
 
The initiation of atherosclerosis is marked by the accumulation of lipid substances 
in the subendothelial layer of major arteries, followed by adhesion and transmigration of 
monocytes to the extracellular matrix (ECM). Cellular adhesion molecules (CAMs) and 
chemokines participate in the transmigration of monocytes during the formation of 
atherosclerotic lesions. Monocyte chemoattractant protein-1 (MCP-1) direct monocytes 
to the site of inflammation by forming concentration gradients within the ECM. Many 
studies use two-dimensional (2D) cell culture models to study monocytes migration; 
however, these models lack the ECM to investigate the formation of MCP-1 gradients 
within the matrix. In this work, an advanced three-dimensional (3D) in vitro vascular 
tissue model was introduced as a novel tool to study the mechanisms occurring within the 
ECM that drive monocytes migration. The 3D model consists of human aortic endothelial 
cells (HAEC) grown on a collagen matrix to better mimic the human artery and 
surrounding ECM. The main objective of this study was to determine the effect of MCP-
1 local concentration gradients within the ECM on monocytes migration. To meet the 
objective, the 3D tissue model was compared to a 2D model that lacks a matrix and free 
MCP-1 is diluted in the surrounding medium. Experimental results showed that HAEC 
on the 2D models had significantly higher CAMs expression than the 3D models after 24 
h stimulation. There was no significant difference in MCP-1 expression between models. 
A greater number of monocytes transmigrated across the endothelium in the 3D tissue 
model compared to the 2D model. A mathematical model was derived to estimate MCP-1 
concentrations within the 3D model at various time points and locations within the 
matrix. The mathematical model indicates that concentration gradients of both free and 
bound MCP-1 are formed inside the collagen matrix, and the concentration of bound 
MCP-1 surpasses the free MCP-1 after 12 h. The results of this research have provided 
new information regarding the relationship between MCP-1 concentration gradients and 
monocytes transendothelial migration, due to the effect of haptotactic gradients. The 3D 
tissue model can also be used to study cellular mechanisms associated with other types of 
chronic inflammatory diseases. 
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CHAPTER 1 
 
 
Introduction 
 
1.1 Background and literature review  
Cardiovascular disease (CVD) is a major health problem in the world and is one of the 
leading cause of death in many developed countries. Heart disease and stroke statistics show that 
more than 200,000 and 830,000 people die from CVD in Europe and USA each year, respectively 
[1, 2]. The latest National Vital Statistics released by the centers for disease control and 
prevention (CDC) reports that in United States, heart and cerebrovascular (stroke) diseases are the 
first and the fifth leading causes of death, respectively [3]. Both diseases can be complications of 
atherosclerosis. 
Atherosclerosis is the primary cause of CVD, including heart attack and stroke [4, 5]. 
Atherosclerosis is initiated by endothelial dysfunction, inflammation, and extracellular matrix 
(ECM) remodeling [5, 6]. Plaque formation begins with a subendothelial accumulation of lipid 
substances, followed by the adhesion of monocytes and lymphocytes to endothelial cells and their 
subsequent migration across the endothelial layer to the ECM where they differentiate into 
macrophages and foam cells by consuming lipid substances and interacting with low density 
lipoprotein [7-13] (Fig. 1). Then, the foam cells start producing inflammatory signals that can 
cause recruitment of monocytes to the area and the development of an atherosclerosis lesion [13]. 
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As shown in Fig. 2, plaque formation can significantly reduce blood flow in an artery, which may 
cause a stroke or a heart attack. 
 
 
Figure 1. Monocytes adhesion and transmigration cascade through the endothelium [13]. 
 
One of the notable events during the initiation of arthrosclerosis is the adhesion and 
transmigration of leukocytes, such as monocytes and lymphocytes from the blood to the site of 
inflammation [5, 7, 11, 12, 14-16]. This adhesion and transmigration involves several steps, 
including slow rolling, adhesion, crawling, paracellular and transcellular migration, and 
transmigration through the basement membrane. The steps are mediated by many bioactive 
molecules that are expressed on the endothelium and by the leukocytes [11, 13, 15, 17, 18]. These 
molecules are called cellular adhesion molecules (CAMs) and chemotactic cytokines 
(chemokines). 
CAMs are proteins expressed on the surface of the cells and are involved in the adhesion 
of monocytes to the endothelial cell layer [5, 11-13, 15, 18-20]. The CAMs that are relevant to 
vascular diseases include vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1), and platelet endothelial adhesion molecule-1 (PECAM-1). 
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There is a low to negligible expression of VCAM-1 on unstimulated endothelial cells, 
and a significant upregulation of VCAM-1 after inflammation. There is an increase of VCAM-1 
expression on endothelial cells in an atherosclerosis prone-sites [21, 22]. Pro-inflammatory 
cytokines, such as interleukin-1β and tumor necrosis factor-α (TNF-α), can stimulate VCAM-1 
expression in the endothelium. 
 
 
Figure 2. Atherosclerotic plaque formation in an artery.  
Picture Source: www.tappmedical.com/atherosclerosis.html 
 
ICAM-1 is expressed on normal endothelium, but the expression is upregulated after 
stimulation by inflammatory cytokines, such as TNF-α [22-25]. ICAM-1 is expressed highly in 
the early stages of atherosclerosis and the immunoreactivity of ICAM-1 was shown to be 
increased significantly at the luminal surface of atherosclerotic lesions [24-29]. 
PECAM-1 is localized on the cell-cell border of confluent endothelial cell monolayers 
and to the luminal side of blood vessels [30, 31]. PECAM-1 is key for the transmigration of 
leukocytes across the endothelium [32] and is not upregulated in response to pro-inflammatory 
cytokines such as TNF-α and interleukin-1 (IL-1) [33-35]. 
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Chemokines are low molecular weight proteins (8-10 kDa) known to have a pivotal role 
in immune cell trafficking and activation [17, 36-40]. Chemokines can form concentration 
gradients as free (fluid phase) or bound (immobilized to the matrix) components [41-48] in the 
ECM. The free and bound chemokines are responsible for the control of different cellular 
mechanisms [47, 49], such as migration pattern of dendritic cells and mononuclear leukocytes 
[46, 48]. The migration of leukocytes from the blood to the tissue site of inflammation is highly 
dependent on chemotactic gradients [45, 50, 51], such as monocyte chemoattractant protein-1 
(MCP-1). MCP-1 (chemotactic toward monocytes and T cells) [52] plays a role in monocytes 
trafficking across the endothelial layer in an early stages of atherosclerosis [53-55]. The most 
important feature of MCP-1 is the chemotactic effect on monocytes in both in vitro and in vivo 
micro-environments [55, 56]. MCP-1 expression is highly upregulated in an atherosclerotic lesion 
[54, 57-60], and the formation of an atherosclerotic lesion decreased significantly in the murine 
models lacking MCP-1 [61, 62]. 
Previous in vitro studies demonstrated that the migration of monocytes is directed by a 
chemotactic gradient of free MCP-1; however, information about the formation of such a gradient 
across the endothelial layer is limited [63-67]. It is known that MCP-1 is secreted from 
endothelial cells in a free form [68], and when the endothelial cells are stimulated, the secretion 
of MCP-1 was found to be non-polarized [66]. Based on these two findings, it was suggested that 
in vivo, MCP-1 secreted from the apical side of the endothelium was removed continuously by 
blood flow into the vascular lumen, while the MCP-1 secreted from the basal side diffused into 
the ECM, thus forming a transendothelial gradient of MCP-1 [66, 68]. 
Chemokines can bind with the endothelial cell surface and ECM proteins, where the 
chemokines can be localized and immobilized, forming bound gradients. The binding is believed 
to be mediated by macromolecule polymers called glycosaminoglycans (GAGs) [44, 47, 69-75]. 
GAGs on the cell surface and in the ECM can interact with chemokines [44, 47, 69, 70, 72, 75-
81] and prevent chemokines from diffusing and being washed away by the blood shear flow [47, 
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74, 75, 82, 83]. The localized chemokine gradient can direct leukocytes from the blood flow to 
the subendothelial layer [72]. 
Handel et al. believe that GAG-chemokine binding interaction is a necessary factor in 
leukocyte extravasations [74]. The binding between GAG and chemokine is proposed to be ionic, 
which can be broken by a sodium chloride saline solution [47, 83]. GAGs can also interact with 
type 1 collagen [84, 85]; therefore, GAG can act as a mediator between MCP-1 and collagen. 
Further, evidence from a study by Distler et al. has shown that if the binding reaction exists, it is 
an irreversible reaction [86]. Several studies have investigated chemokine-GAG interaction in the 
ECM in vivo [71-74, 79, 83]; however, the interaction could not be assessed in vitro [72, 83, 87] 
due to the lack of the proper environment to form the haptotactic concentration gradient.  
Previous studies have used two-dimensional (2D) experimental systems to investigate the 
effect of chemokines on monocytes migration [65, 88-90]. Traditional 2D cell culture models 
may not be suitable predictors of what occurs in more complex three-dimensional (3D) tissue 
models, like those within the human body [91]. In a 2D model, endothelial cells are grown on a 
thin, microporous membrane, a chemokine is added to the liquid media below the membrane, 
monocytes are added to the apical surface of the endothelial cells, and transmigration of the cells 
across the endothelial cell layer and the microporous membrane is observed [92]. The chemokine 
is added to both the top and bottom chambers for a chemotactic control [90]. The system is 
adequate for showing a response of monocytes to a chemokine that has formed an artificial 
concentration gradient across the endothelial cell layer. However, the diffusive concentration 
gradient could not be assessed in the 2D models where the free proteins are quickly diluted in the 
surrounding medium. In the 2D models, endogenous MCP-1 released by the cells to the 
surrounding liquid media is diluted, quenching the chemoattractant effect. Therefore, a high 
concentration of MCP-1, relative to in vivo conditions, must be added to the bottom chamber to 
elicit a chemotaxis response [17, 36, 40, 44, 47, 48, 71, 72, 93-96].  
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A better alternative experimental model is a 3D model consisting of a matrix to mimic 
the subendothelial ECM. In this study, a collagen matrix is used to represent the ECM and 
endothelial cells are grown on the surface of the matrix. The major advantage of the 3D model is 
that the third dimension provides the supplementary space that is significant for the creation of 
diffusive concentration gradients in the ECM. Apart from this advantage, when focusing on the 
transmigration of monocytes, this matrix can also provide an appropriate model to investigate the 
effect of diffusive concentration gradients of MCP-1 on monocytes migration. The 3D model 
provides an area for monocytes to localize and differentiate after the transendothelial migration. 
Comparison between the 3D in vitro vascular tissue model and the 2D cell culture model is 
shown in Fig. 3. 
 
 
Figure 3. The schematic diagram of (A) a 3D in vitro vascular tissue model consisting of a 
collagen matrix would be a better experimental model to mimic the ECM. The 3D tissue model 
provides the added dimension that is important for the creation of a diffusive concentration 
gradient formed in the ECM, which is responsible for the control of many cellular mechanisms, 
and (B) a 2D cell culture model where endothelial cells are grown on a thin, microporous 
membrane, the chemokine is added to the aqueous media below the membrane, monocytes are 
added to the apical surface of the endothelial cells, and  transmigration of the cells across the 
endothelial cell layer and the microporous membrane is observed. 
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In this study, an advanced 3D in vitro vascular tissue model was introduced as a novel 
tool to study the MCP-1 concentration gradients and determine the monocytes migration response 
to the gradients. Overall, the main objective of this work was determining the effect of MCP-1 
local concentration on monocytes migration in the 3D tissue model and comparing the outcomes 
to the 2D model results. We hypothesized that the MCP-1 concentration gradient within the ECM 
of the 3D tissue model drives a different cellular response than that in the 2D model.  
 
1.2 Project objective and specific aims 
The main objective of this study was to determine the effect of MCP-1 local 
concentration gradients on monocytes migration by using a 3D tissue model and comparing the 
outcomes to a 2D model. We hypothesized that the MCP-1 concentration gradient within the 
ECM of the 3D tissue model will drive a different cellular response than that in the 2D model. To 
meet the objective of the proposed work, the following specific aims were completed:  
1) Compare the expression of selected CAMs and MCP-1 on the surface of 
endothelial cells in the 3D in vitro vascular tissue model to those in the 2D cell culture 
models during inflammation. CAMs are critical participants in the adhesion of monocytes into 
the atherosclerosis lesion. Therefore, measuring the expression of CAMs and MCP-1 on the 
surface of the endothelial cells within the 3D and 2D models is necessary to later facilitate 
understanding the monocytes migration process.  
2) Compare the release of MCP-1 from cells within the 3D in vitro vascular tissue 
model to those in the 2D cell culture models during inflammation. MCP-1 released from the 
endothelial cell layer can diffuse into the ECM and form concentration gradients that can have an 
effect on monocytes migration. Hence, this step quantifies the concentration of released MCP-1 
within the 3D and 2D models. The amount of MCP-1 released from the endothelial cells in the 
3D tissue model was used to develop a mathematical model that could be used to determine the 
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MCP-1 concentration gradients within the matrix of the 3D tissue model at various time points 
and locations. 
3) Determine the effect of MCP-1 release on monocytes transmigration during 
inflammation. In order to investigate the potential differences in monocytes migration due to the 
concentration gradient associated with the 3D in vitro vascular tissue model, monocytes adhesion 
and transmigration across the endothelium was compared to the 2D cell culture model.  
 
Overall, the outcome from this project will provide 1) new information regarding the 
effect of MCP-1 local concentration gradients on monocytes transendothelial migration during an 
inflammatory response, and 2) a comparison of how cells generally behave within a 3D tissue 
model versus a 2D model. The results can be used to develop therapeutic strategies for chronic 
inflammatory diseases that can then be tested in the 3D tissue model.  
 
1.3 Project significance 
This project is significant because it provides new information about the early stages of 
atherosclerosis and a novel 3D tissue model that can potentially be used to test therapeutics for 
atherosclerosis. The 3D tissue model was used to predict local concentration gradients of MCP-1 
within the ECM and to determine the effect on monocytes migration, associated with the early 
stages of atherosclerosis. Previous work has shown that MCP-1 can bind to ECM proteins and 
form a bound concentration gradient within the ECM. Therefore, the model was used to 
determine the contribution of both free and bound MCP-1 gradients within the ECM. The 3D 
tissue model was compared to existing 2D models in order to show the influence of the ECM 
making up the third dimension on cell behavior. The expression of CAMs on the endothelial 
cells, MCP-1 release, MCP-1 diffusive gradients, and monocytes migration were compared 
between the 3D and 2D models. Findings from comparing the two systems contribute to a better 
 9 
  
understanding of how cells behave in 2D versus 3D models and the development of an improved 
experimental system. 
 
1.4 Preliminary studies 
Monocytes are a type of blood immune cells known to transmigrate across the endothelial 
cell layer continuously. The end state of the monocytes after extravasations is highly dependent 
on many factors, including the tissue involved in the process, the kind of stimulus (hyperglycemia 
and TNF-α), and the chemokine concentration gradient in the tissue. These factors were 
investigated in preliminary studies and the relevant results were used to define the current work. 
The first subsection describes initial studies of using a 3D tissue model to investigate the effect of 
glucose concentration on endothelial cell behavior [97]. Studies were performed to examine 
changes in cell function associated with inflammation by measuring the expression of key cell 
surface proteins and leukocyte migration across the endothelium. The remaining subsections 
describe preliminary work that shows MCP-1 concentration profile formation in the ECM [98] 
and the effect on monocytes migration. The binding reaction between MCP-1 and the collagen 
matrix is also investigated. 
 
1.4.1 The effect of hyperglycemia on endothelial cells behavior and monocytes migration 
and differentiation in a 3D tissue model 
Hyperglycemia is one of the common complications associated with diabetes and is an 
inflammatory signal that enhances leukocyte migration across the endothelium. To date, studies 
to characterize monocytes migration and differentiation in response to hyperglycemia have not 
been conducted. An initial study conducted by Shukla et al. [97] investigated the use of a 3D 
tissue model to investigate the effect of hyperglycemia on endothelial cell dysfunction and on 
immune cell trafficking and differentiation [97].  
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Briefly, Human Umbilical Vein Endothelial Cells (HUVEC) were seeded on top of the 
collagen matrix within microwell plates. The cells were incubated with 15 and 30 mM glucose 
concentration in the culture media for nine hours periods to represent hyperglycemic conditions.  
The addition of 5.6 mM glucose (normoglycemia) and 10 ng/ml TNF-α (inflammation) were used 
as negative and positive controls, respectively. The studies were performed to examine changes in 
cell function by measuring expression of key cell surface markers associated with inflammation 
and leukocyte migration across the endothelium. The cell surface expression of PECAM-1, 
VCAM-1, ICAM-1, and E-selectin was detected on the cells surface. Expression of VCAM-1 was 
only detected for the 30 mM and positive control samples (TNF-α) but not for the 5.6 mM and 15 
mM samples, indicating that this adhesion molecule plays a possible role in leukocyte recruitment 
for the tissue model. PECAM-1 was detected for all of the samples tested with no significant 
difference among the samples. E-selectin was not detected for any of the samples tested in 
comparison with the appropriate isotype control. ICAM-1 was only detected for the positive 
control sample (TNF-α). The supernatants from the samples were also collected and soluble 
VCAM-1 was measured by ELISA which showed a detectable level of sVCAM-1 within the 
culture supernatant for a positive control.  
Further preliminary studies were performed with the 3D model to investigate the effect of 
glucose concentration on leukocyte migration and differentiation [97]. After incubation with high 
concentrations of glucose, the medium was removed and samples were washed, and seeded with 
PBMCs. Leukocyte migration and cell differentiation characteristics were determined after 
sample collection. It was shown that the total number of cells in the tissue was increasing after 2 
and 48 h incubation as the glucose concentration increased. However, there was no significant 
change in the reverse-transmigrated cells after 48 h. Furthermore, no significant migration of B-
cells (CD19+) or natural killer cells (CD56+) cells across the endothelium into the 
subendothelium space was observed. However, a significant migration of monocytes (CD14+) 
and T-cells (CD3+) cells were observed across the endothelial cell layer. There was also a 32% 
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increase in the number of cells in the subendothelial matrix that were differentiated into 
macrophages in response to an increase in glucose concentration which showed that the high 
glucose concentration altered the proportion of monocyte-derived dendritic cells to monocyte-
derived macrophages.   
This preliminary work demonstrated the feasibility of applying a 3D model to study cell 
behavior which included: 1) growing a confluent endothelium on a matrix to represent the ECM, 
2) endothelial cell response to different stimulus, such as hyperglycemia and TNF-α, and 3) 
transmigrating and differentiation of monocytes in the subendothelial space as the local 
concentration of glucose in the model is increased. 
 
1.4.2 MCP-1 and collagen binding reaction test 
To focus on the diffusive and kinetic behavior of MCP-1 in the collagen matrix, a 
simplified collagen matrix without endothelial cells was used by Leemasawatdigul et al. [98]. 
Complete medium with a known concentration of MCP-1 was added to the top of the simplified 
collagen model and incubated at standard conditions for a set time period to allow MCP-1 to 
diffuse from the top reservoir through the collagen matrix and to the bottom chamber. At the end 
of the incubation time point, the amount of MCP-1 in the solutions from the top and bottom 
chambers were analyzed by the enzyme-linked immunosorbent assay (ELISA), and the total 
concentration of MCP-1 in the collagen matrix was calculated. Results showed that the 
concentration in the collagen matrix was higher than the concentration of MCP-1 which was 
added initially to the top reservoir. At equilibrium, the concentration of MCP-1 in the top 
chamber, collagen, and bottom chamber should be equal. A higher concentration than the initial 
indicated that a reaction is present that consumes MCP-1 or transforms MCP-1 from the free 
form. This result indicated that MCP-1 can bind with the collagen and forms a bound 
(nonsoluble) form of MCP-1. 
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 This finding is significant because it was shown that MCP-1 can bind to ECM 
components and produce bound complexes across the matrix. The finding was used in the current 
project of a more complex system that includes endothelial cells grown on the collagen matrix 
that secret MCP-1. Released MCP-1 from the cells can diffuse through the matrix and bind with 
collagen. 
 
1.4.3 Derivation of a mathematical model to describe the transport of MCP-1 through a 3D 
collagen matrix without cells 
Diffusion of MCP-1 in the 3D simplified collagen matrix without endothelial cells was 
modeled as unsteady-state diffusion in one dimension by Leemasawatdigul et al. [98]. The 
equation of continuity, along with experimental data, was used to derive a mathematical model 
that can be used to estimate MCP-1 concentration gradients within the 3D model. The Crank-
Nicolson numerical method was selected to solve the partial differential equation with initial and 
boundary conditions. The values for the model constants, Kb (reaction rate constant) and DM׀C 
(diffusive coefficient of MCP-1 through the collagen matrix) were determined as 0.858 h−1 and 
0.108 mm2 h−1, respectively, by fitting the mathematical model to selected experimental data. The 
concentration profiles of free and bound MCP-1 in the collagen matrix at set time points were 
calculated by using the mathematical model. Results of the mathematical model show that the 
concentration gradient of free MCP-1 decreases overtime, whereas the gradient of bound MCP-1 
increases. This finding suggests that apart from the gradient of free MCP-1, the gradient of bound 
MCP-1 is another potent factor that may mediate monocytes transendothelial migration. For the 
current project, the mathematical model was modified and solved for a more complex system that 
includes a source term to account for MCP-1 production from the endothelial cell layer above the 
collagen matrix. The modified mathematical model provides a way to study the formation of the 
gradient of MCP-1 that is secreted from endothelial cells and the effect of the gradient on 
monocytes migration involved in the early stages of atherosclerosis. 
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1.4.4 The haptotactic effect of MCP-1 on monocytes migration 
Previous studies demonstrated the existence of the binding reaction between MCP-1 and 
collagen. Additional studies were performed to measure the haptotactic effect of MCP-1, from the 
bound MCP-1 within the 3D model. Briefly, 50 ng/ml of MCP-1 was added to the top of the 
collagen matrix. After 24 h incubation period, the top and bottom solutions were collected, and 
the collagen matrix was washed three times to ensure that all free MCP-1 was removed from the 
collagen matrix. The concentration of MCP-1 in the top and bottom solutions, along with the 
three wash solutions was measured by the ELISA. A total mass balance for the closed system was 
used to calculate the concentration of MCP-1 in the collagen matrix. Results showed that 40% of 
the MCP-1 that was originally added to the top of the collagen matrix and incubated for 24 h, 
remained in the collagen matrix. The final concentration of MCP-1 in the collagen matrix after 
three successive washes was four times higher than the initial concentration.  
Further, the migration of monocytes into the collagen matrix with bound MCP-1 (as 
described above) was compared with migration of monocytes into collagen that was not treated 
with MCP-1. The results revealed that the total number of monocytes that migrate into the 
collagen matrix with MCP-1 increased significantly compared to when the collagen was not 
treated. The results from this study demonstrated that in addition to the gradient of free MCP-1, a 
gradient of bound MCP-1 (haptotactic gradient) was also formed in the collagen matrix as a result 
of the binding reaction, which can induce monocytes trafficking in to the collagen matrix of the 
3D model. The effect of the free/bound gradient of MCP-1 released from endothelium on 
monocytes transmigration was investigated in the current project. 
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CHAPTER 2 
 
 
Effects of Local Concentration Gradients of Monocyte Chemoattractant Protein-1 on 
Monocytes Adhesion and Transendothelial Migration in an 
In Vitro Three-Dimensional Tissue Model 
 
2.1 Introduction 
Atherosclerosis, the primary cause of cardiovascular disease (CVD) [4, 5], is an 
inflammatory disease and is characterized by endothelial dysfunction, inflammation, and 
extracellular matrix (ECM) remodeling [5, 6]. Atherosclerotic plaque formation begins with 
accumulation of lipids in the subendothelial layer of major arteries, followed by the adhesion of 
monocytes and lymphocytes to the endothelium, and the subsequent recruitment of these cells 
across the endothelium and into the ECM [7-12]. Plaque formation can significantly reduce blood 
flow in an artery, which may cause a stroke or heart attack. The adhesion and transmigration of 
leukocytes across the endothelium include their rolling, adhesion, and crawling which is followed 
by their paracellular and transcellular migration through the basement membrane [67, 99]. 
Generation of inflammatory signals regulates cellular movement and differentiation of leukocytes 
from the circulation into the injured tissue in order to aid in wound healing processes. Cellular 
adhesion molecules (CAMs) and inflammatory chemotactic cytokines (chemokines) are 
responsible for the recruitment of leukocytes to the site of inflammation.  
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Many cardiovascular diseases, such as atherosclerosis, induce inflammation and result in 
the over-recruitment of leukocytes [10, 38, 40, 52, 54]. Past studies show that specific chemokine 
profiles dictate the migration of leukocytes to the site of inflamed tissue [40, 66].  
CAMs are proteins expressed on the surface of the cells and are involved in the adhesion 
of monocytes to the endothelial cell layer [5, 11-13, 15, 18-20]. The CAMs that are relevant to 
vascular diseases include vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1), and platelet endothelial adhesion molecule-1 (PECAM-1). Chemokines 
are low molecular weight proteins (8-10 kDa) known to have a pivotal role in immune cells 
trafficking and activation [17, 36-40]. The migration of leukocytes from the blood to the tissue 
site of inflammation is dependent on chemotactic gradients [45, 50, 51], such as monocyte 
chemoattractant protein-1 (MCP-1). MCP-1 (chemotactic toward monocytes and T cells) [52] 
plays a role in monocytes trafficking across the endothelial layer in early stages of atherosclerosis 
[53-55]. Furthermore, it has been shown that MCP-1 expression is highly upregulated in an 
atherosclerotic lesion [54, 57-60], and the formation of the lesion decreased significantly in the 
murine models lacking MCP-1 [61, 62]. 
Previous in vitro studies illustrate that the transendothelial migration of monocytes 
depends on the concentration gradient of free MCP-1 across the endothelial layer [63-67, 88-90]. 
The highest concentration of MCP-1 is at the source of atherosclerotic inflammation in the 
arterial walls [38]. Further, MCP-1 is shown to be secreted from the endothelial cell layer in a 
free form [68], and when the endothelial cells are stimulated, the secretion of MCP-1 was found 
to be non-polarized [66]. Based on these two findings, it was suggested that in vivo, MCP-1 
secreted in the luminal side could be prevented by the blood flow into the vascular lumen, while 
the concentration gradient of MCP-1 is formed within the ECM via the diffusion of MCP-1 
released from the basal side of the endothelial cell layer into the subendothelial ECM [68]. 
Therefore, formation of the MCP-1 concentration gradient is driving monocytes migration into 
the ECM. However, in response to an inflammatory stimuli, influx of monocytes to the site of 
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injury increases dramatically, and an atherosclerosis lesion may develop, which is the basis of 
pathology in atherosclerosis. Presently, profiling the development of MCP-1 gradients in the 
ECM is still lacking; due to there are no available techniques that can be used to quantify such 
gradients. 
Two-dimensional (2D) cell culture models have been used to investigate the effect of the 
concentration gradient of free MCP-1 on monocytes migration [88-90]. The model is adequate for 
showing a response of monocytes to a chemokine that has formed a concentration gradient across 
a membrane with/without the endothelial cell layer; however, the 2D model cannot be used to 
examine chemokine concentration gradients that are present within the tissue in vivo [17, 36, 40, 
44, 47, 48, 71, 72, 93-96]. In the 2D experimental model, endogenous MCP-1 released by the 
cells to the surrounding liquid media is diluted, quenching the chemoattractant effect. Hence, the 
model has been used to investigate monocytes migration in response to free exogenous 
chemokines. Using 2D models for chemotaxis studies can be too simplistic and overlook what 
occurs in vivo due to the lack of a third dimension [91] and they may not be suitable for 
predicting what occurs in a complex three-dimensional (3D) model, like those within the human 
body [91]. A better alternative experimental model is a 3D model consisting of a collagen matrix 
to mimic the subendothelial ECM as proposed here. In this study, an advanced 3D in vitro 
vascular tissue model (defined as 3D tissue model throughout the text) was introduced as a tool to 
study the underlying mechanisms occurring within the ECM in atherosclerosis. The major 
advantage of the 3D tissue model is that the third dimension provides the supplementary space 
that is significant for the creation of MCP-1 diffusive concentration gradients in the ECM, which 
is responsible for the control of many cellular mechanisms. 
In the previous study, we have demonstrated the formation of the MCP-1 diffusive 
concentration gradient in a simplified, cell-free 3D matrix and have derived a mathematical 
model to describe the such a gradient [98]. In this study, human aortic endothelial cells (HAEC) 
are added to the model to form an endothelium on the surface of a collagen matrix used to 
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represent the ECM. MCP-1 released from the endothelial cell layer can diffuse into the ECM and 
form localized concentration gradients which can influence the monocytes migration. The goal of 
the current study is to investigate the effect of MCP-1 local concentration gradients on monocytes 
migration in the 3D tissue model and compare the outcomes to the existing 2D model results. We 
hypothesize that the MCP-1 concentration gradient within the ECM of the 3D tissue model would 
drive a different monocytes migration response than in the 2D model based on the difference in 
the nature of existing concentration gradients in the 3D and 2D microenvironments. 
HAEC growth characteristics (i.e., viability, trans-endothelial electric resistance, and 
morphology), the kinetic and magnitude expression of the CAMs (VCAM-1, ICAM-1, PECAM-
1) and MCP-1, and transport properties (MCP-1 release profile) is also studied between the 2D 
and the 3D models. The experiments are performed under quiescent conditions and when models 
are immunologically activated with tumor necrosis factor-α (TNF-α). TNF-α was used to mimic 
inflammation that occurs in the early stages of atherosclerosis. Differences between two models 
characteristics, such as endothelium cell behavior, MCP-1 diffusive concentration gradients, and 
their effect on monocytes transendothelial migration will help us to have a better understanding of 
underlying mechanisms during an inflammatory response in early stages of atherosclerosis. The 
results of this research will lead to the development of an improved in vitro model to test 
therapeutic strategies associated with inflammatory diseases. 
 
2.2 Methods 
2.2.1 Cell culture 
Human aortic endothelial cells (HAEC) and endothelial cell complete medium were 
purchased from PromoCell, Heidelberg, Germany. HAEC were cultured in 75 cm2 flasks and 
incubated at standard conditions (37 °C and humidified atmosphere of 5% CO2) and used at 90% 
confluence. 
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2.2.2 Preparation of the 3D in vitro vascular tissue model 
Costar (Corning life sciences, Cambridge, MA) and ThinCert Transwells (Greiner Bio-
one, Frickenhausen, Germany) with 8.0 μm permeable membranes were used to create the 3D 
tissue model in 24 and 12-well inserts, respectively. The inserts provide easy access to the free 
factors released in the apical and basal compartments of the endothelial layer in the 3D tissue 
model for taking measurements that makes them more advantageous than other models. Collagen 
type I solution of the 3D tissue model was prepared using previously described protocols [97, 98] 
and added to the top of the membrane (78 and 266 μl per well for 24 and 12-well inserts, 
respectively). Plates were incubated at standard conditions to form a gel. Complete medium was 
added to the upper and lower chambers and incubated overnight to equilibrate the collagen 
matrices. The next day, the gel was coated with fibronectin (Biomedical Technologies, 
Stoughton, MA) and seeded with HAEC (7.5*104 cells/cm2). The cells were incubated and used 
for experiments at one day after reaching confluency and forming an endothelium by visual 
observation (Fig. 4). 
To construct the collagen-coated and 2D models, membranes (8.0 μm pore size) were 
coated with collagen (15 μl per well for 24-well format inserts) and fibronectin; or fibronectin 
only, respectively, seeded with HAEC as stated above, and used at one day post-confluence.  
 
Table 1. 24-well format membrane insert characteristics 
Membrane 
Material 
Growth 
Area  
Membrane 
Thickness 
Pore 
Density 
Pore        
Size  
Optical 
Quality 
Polycarbonate 0.33 cm2 10.0 μm 
1*105   
pores/cm2 
8.0 μm Translucent 
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Figure 4. The steps to construct the 3D tissue model within the Transwell permeable supports. 
Briefly, a 57.1 vol % bovine collagen type I solution was prepared and added to the top of the 
membrane and incubated at 37 °C and 5% CO2 to form a gel. Complete endothelial cell growth 
medium was added to the top and bottom chamber and incubated overnight at standard conditions 
to equilibrate the collagen matrices. The next day, the matrices were seeded with HAEC (7.5*104 
cells/cm2) and cells confluency was monitored everyday by visual observation. Samples were 
used for experiments at post-day reaching confluency. 
 
2.2.3 HAEC viability and trans-endothelial electric resistance  
Viability and unit area resistance of HAEC layer were measured under normal and 
activated conditions. To activate the HAEC, 10 ng/ml recombinant human TNF-α (R&D 
Systems, Minneapolis, MN) in complete medium was added to the apical surface of the HAEC, 
and the cells were analyzed at 1 and 24 h incubation. These times were selected in order to study 
cells behavior at both early and late time points. Samples treated for 24 h with Triton X-100 (1%, 
v/v) (Fisher Scientific, Pittsburgh, PA) were used as a negative control (NC) for cell death, and 
samples in complete media was used as a positive control (PC). 
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Viability was measured using CellTiter-Blue® assay (Promega, Madison, WI) following 
the manufacturer's protocol (Fig. 5). This assay measures cellular metabolism by measuring the 
conversion of the dye resazurin to the fluorescent product resorufin, and only viable cells are able 
to reduce the former to the latter. Fluorescent intensities of the samples were measured using a 
fluorescent microplate reader (SpectraMax Gemini XS, Molecular Devices, Sunnyvale, CA) at 
excitation and emission spectra of 560 and 590 nm, respectively, and reported as relative 
fluorescent unit (RFU). Unit area resistance of the HAEC cultured in the models was also 
determined by measuring the trans-endothelial electric resistance (TEER) (WPI, Sarasota, FL) 
following the manufacturer's protocol (Fig. 6). Average relative fluorescent intensities and unit 
area resistance of the HAEC obtained under normal and activated conditions were subtracted 
from the negative control values in order to obtain the true cell layer viability and resistance. 
 
 
Figure 5. Cell Titer-Blue cell viability assay. Promega Corporation. Technical Bulletin 2009. 
[cited; Available from http://www.promega.com/tbs/tb317/tb317.pdf] 
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Furthermore, HAEC grown on collagen coated models were also used as control samples 
for the endothelium cultured on collagen matrices to investigate if the collagen per se could affect 
the cell behavior significantly. Average unit area resistance of the confluent HAEC grown on 
models were reported under normal conditions and subtracted from the unit area resistance of the 
cell free samples considered as background controls (BG). 
  
 
Figure 6. Trans-endothelial electric resistance (TEER) instrument. 
Picture source: http://www.wpiinc.com/pdf/endohm-im-041408.pdf 
 
2.2.4 HAEC morphology 
HAEC were stained with media containing fluorochrome-conjugated PECAM (5 µg/ml) 
or isotype antibodies (Biolegend, San Diego, CA) according to standard cell staining protocol 
(BD Bioscience, San Jose, CA). The stained samples were removed from the inserts, mounted on 
slides, and the cells nuclei were counterstained with DAPI using ProLong® Gold antifade reagent 
(Invitrogen, Carlsbad, CA). Samples were examined by confocal microscopy to detect the cells 
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nuclei and membrane. Images were analyzed using ImageJ software (version 1.49t) to determine 
the membrane surface areas of 50 cells per three independent samples. 
   
2.2.5 Expression of CAMs and MCP-1 on the endothelial cell surface 
The surface expression levels of VCAM-1, ICAM-1, PECAM-1, and MCP-1 were 
measured under normal and activated conditions. Cells were activated by adding TNF-α to the 
apical side of the endothelium, as mentioned before, and samples were analyzed after 1, 6, 12, 18, 
and 24 h incubation time points for the expression of CAMs and MCP-1. HAEC cell culture 
models incubated without TNF-α served as controls. For flow cytometry, cells were detached 
from the 2D model using human primary endothelial cell detach kit containing solution of 0.25% 
trypsin with EDTA (PromoCell), and membrane inserts were washed to collect the lifted cells. To 
remove the HAEC from the 3D tissue model, the collagen matrices were digested with 
collagenase D (Roche Applied Science, Indianapolis, IN). Briefly, collagenase D was added on 
the collagen matrices and incubated at culture conditions for 1-2 h to digest the matrices and the 
wells were washed to collect all detached cells. Cell suspensions were centrifuged (5 min, 1200 
rpm, 4 °C), and immunofluorescence staining was done using anti-human fluorochrome-
conjugated CD106 (VCAM-1), CD54 (ICAM-1), CD31 (PECAM-1), MCP-1 or isotype controls 
(all from Biolegend, San Diego, CA). A flow cytometer (FACSCalibur) was used to analyze the 
cells within a day of staining and data analyses were performed using FCS Express software 
(version 3) (Fig. 7). For each sample, uniform population of the endothelial cells were gated using 
side versus forward scatter plots to exclude dead cells and debris. The Overton subtraction 
method was used to determine percentage positive (PP) and net mean fluorescent intensity (MFI) 
of the cells population compared to the isotype controls for each marker [58]. The PP and MFI 
results of the activated HAEC were normalized to the values obtained for the control samples 
(media with no TNF-α stimulation). 
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Figure 7. Detecting/measuring CAM/MCP-1 expression on the HAEC. 
 
2.2.6 Release of MCP-1 within the 3D tissue model 
The kinetics of MCP-1 release from the HAEC grown in the 2D and 3D models in 12-
well inserts were measured under normal and activated conditions. Cells were activated with 
TNF-α (as described previously), and MCP-1 release was quantified at 1, 6, 12, 18, and 24 h 
following addition of TNF-α. Culture models incubated without TNF-α were used as controls. To 
measure MCP-1 release from the 2D and 3D models, media from both the apical and the basal 
compartments of the endothelium were collected and stored separately at -20 °C. To quantify 
MCP-1 concentration in the matrix, the collagen matrix was digested by collagenase D (as 
described before), centrifuged, and the cell-free supernatants were stored at -20 °C. MCP-1 
concentration was measured in the collected solutions using a human MCP-1 ELISA kit (BD 
Biosciences) following the manufacturer’s protocol. Then, based on the collagen matrix volume 
calculations (manuscript in review) and the measured MCP-1 amount in the digested collagen 
solutions, MCP-1 concentration in the collagen matrices were determined (Fig. 8). 
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Figure 8. Measuring the MCP-1 kinetics from HAEC in response to TNF-α. 
  
2.2.7 Preparation of monocytes 
Human peripheral blood mononuclear cells (PBMCs) were isolated from blood obtained 
from healthy donors (Oklahoma Blood Institute, Oklahoma City, OK), using a Ficoll-Plaque (GE 
Healthcare, Uppsala, Sweden) density gradient centrifugation method. Monocytes were 
negatively selected from the PBMCs using a pan-monocyte isolation kit (Miltenyi Biotech, 
Auburn, CA) using the manufacturer’s protocol, and used immediately for adhesion and 
migration experiments. 
 
2.2.8 Monocytes adhesion and transendothelial migration 
Adhesion and migration of monocytes under normal and activated conditions were 
studied in both the 2D and 3D models in 12-well inserts. Activation was achieved by adding 
TNF-α to the HAEC apical layer, and samples were analyzed after 1 and 24 h. At the end of each 
incubation, culture media were removed from the endothelium apical compartment and human 
monocytes (1.5*105 cells/cm2 in 0.5 ml complete medium) were added. After 2 h, samples were 
rinsed gently to remove the non-adherent or loosely adherent monocytes, and the entire cell 
population (HAEC and monocytes) were collected (Fig. 9). Any monocytes that migrated to the 
endothelial basal layer were also collected. Monocytes that either adhered to or transmigrated 
across the endothelium were detected by immunofluorescence staining with anti-human CD14 
fluorochrome-conjugated antibody or isotype control (BD Biosciences). Analysis was performed 
within a day of staining. Monocytes population was gated and the Overton subtraction method 
was used to determine the percentage of CD14 positive cells in each gate compared to the isotype 
controls [58]. Number of monocytes in gates was calculated based on the total number of events 
and the percentage of CD14+ cells in each gate. Then, total number of monocytes in each sample 
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was determined using the number of monocytes in each gate, instrument flow rate, time elapsed 
for collecting the events, and total initial sample volume. 
 
Figure 9. Experimental procedure for examining monocyte adhesion and transmigration in the 3D 
tissue model. 
  
2.2.9 The effect of MCP-1 on monocytes adhesion and migration 
The effect of MCP-1 on monocytes adhesion and migration in the 3D tissue model was 
also studied using an MCP-1 neutralizing antibody. At the end of 1 and 24 h incubation time 
point with TNF-α, media was removed from the HAEC apical compartment and was replaced 
with fresh media containing 750 ng/ml purified anti-human MCP-1 antibody (Biolegend). The 
samples were incubated for 2 h, the media was removed, and monocytes were added to the apical 
side of the endothelium. After 2 h incubation, cells were collected and analyzed, as described 
previously. 
 
2.2.10 Statistical analysis 
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All experiments were performed in replicate to determine the mean ± standard deviation 
(SD) of the samples. A nonparametric statistical analysis of Kolmogorov-Smirnov (K-S) test was 
used to determine if the distribution of cells sizes are equal between independent samples group. 
Student's t-test was used to determine the significantly different groups among pairs. p value of < 
0.05 was considered significant. 
 
2.3 Results 
2.3.1 HAEC viability and trans-endothelial electrical resistance   
 Viability and unit area resistance of the HAEC layer, quantified for both models under 
normal condition and upon activation by TNF-α for 1 and 24 h, are shown in Fig. 10. To compare 
the viability of the HAEC, we measured the metabolic activity as an indicator of viability in the 
cells grown in the models using the Cell-Titer Blue® Assay. No significant difference in cell 
viability is observed for 2D and 3D models with the addition of TNF-α compared to positive 
control (PC) samples (Fig. 10A). Furthermore, HAEC viability is lower in the 3D tissue model 
compared to the 2D model, when cells are activated at early and late time points, but not 
statistically significant. Our results clearly show that the cells in the novel, 3D tissue model retain 
viable. 
Resistance results, shown in Fig. 10B, indicate that cell layer integrity at normal 
condition does not alter significantly within 1 h stimulation in 2D and 3D models. However, 
significant 1.6 and 4.5-fold cell resistance reduction (p < 0.05) is observed after 24 h of 
stimulation compared to the positive control (PC) samples in the 2D and 3D models, respectively. 
TEER measurements results also shows a significant 1.9, 2.2, and 5.2-fold decrease (p < 0.05) in 
cell resistance for the 3D tissue model compared to the 2D model for positive control samples, 
and after 1 and 24 h adding TNF-α, respectively. These results suggest that using collagen matrix 
as the ECM substrate has significant effect on formation of cell-cell junctions and HAEC 
spreading behavior. 
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Figure 10. HAEC viability fluorescent intensity measurements (ex/em: 560/590 nm) (A) and unit 
area resistance (B) in the 2D and the 3D models under normal condition (positive control: PC) 
and when the models were activated with TNF-α (10 ng/ml) for 1 and 24 h. Values are presented 
as mean ± SD of absolute differences compared to the Triton X-100 (1%, v/v) treated samples 
(negative control: NC); n=3; * indicates p value < 0.05. 
 
The foregoing observations led us to further our understanding of the effect of collagen 
material per se as opposed to the collagen matrix ECM on HAEC layer unit area resistance. Fig. 
11 shows the unit area resistance of the HAEC layer grown on the microporous membrane, 
collagen coating, and collagen matrix models, quantified by measuring the TEER under normal 
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condition subtracted from the background (BG) unit area resistance. TEER measurements show a 
significant 2.1 and 1.6-fold decrease (p < 0.05) in cell resistance in the collagen matrix model 
compared to the microporous membrane and collagen coated samples, respectively. The average 
unit area resistance of the cells is decreasing as the collagen volume is increasing in the coated 
and matrix models compared to the 2D model. Therefore, confluent HAEC layer grown in the 3D 
tissue model had the highest permeability under normal condition. 
 
 
Figure 11. HAEC unit area resistance in the microporous membrane, collagen coated, and 
collagen matrix models under normal condition. Values are presented as mean ± SD of absolute 
differences compared to the background (BG); n=3; * indicates p value < 0.05. 
 
The results suggest that endothelium-collagen interaction per se has an influence on cell-
cell junctional zones which has decreased the HAEC resistance. Moreover, it is shown that 
formation of cell-cell junctions pattern not only depends on the interaction of cells and the type of 
material itself used as the substrate, but also the endothelium resistance varies with using the 
substrate as subendothelium ECM as opposed to a single layer coating film.   
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2.3.2 HAEC morphology 
In this section, we sought to investigate the influence of subendothelium substrate and 
ECM on HAEC morphology which led to the observed variations in HAEC unit area resistance in 
section 2.3.1. Representative images of HAEC cultured on the membrane, collagen coating, and 
collagen matrices are shown in Fig. 12A. From microscopy analysis, it is observed that HAEC 
morphology was similar but not identical on the microporous membrane, collagen coated, and the 
matrices. Generally, HAEC were circular and round shape more like cobblestones and in some 
cases appeared more elongated in different models. However, quantitative analysis of HAEC 
sizes in Fig. 12B shows physical variations of cells surface area distribution depending on the 
interaction between cells and their surroundings substrate. 
HAEC grown on the membrane environments exhibit a broad diameter range (22-76 µm) 
compared to the collagen coated models whereas the diameter range is narrowed down (24-73 
µm). However, based on the K-S statistical analysis, HAEC on the collagen coated samples have 
the same size distribution function as the cells grown on the membrane model. Furthermore, sizes 
of HAEC grown on the matrices appeared to be more uniformly developed with a smaller 
diameter range (20-53 µm) and a significant difference (p < 0.01) in distribution function 
compared to the HAEC grown on the membrane and collagen coated models. The significant 
junctional zone distribution difference of HAEC grown on the collagen matrices compared to the 
microporous membrane and collagen coated samples suggests that the endothelium unit area 
resistance ought to be different between the samples which matches the data shown in Fig. 11. 
These data suggest that not only collagen material itself had an effect on biophysical morphology 
behavior of HAEC, but also having an ECM under an endothelium altered cells growth and 
spreading properties. 
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Figure 12. HAEC were immunostained for the nuclei and endothelial marker PECAM-1. (A) 
Confocal microscopy was used to image the aortic endothelial cell shape in microporous 
membrane, collagen coated, and collagen matrix models. Nuclei and PECAM protein expression 
were revealed by DAPI staining (blue) and CD31 antibody (red), respectively. All the images 
were taken at the same magnification of 400× and at the same settings as their staining isotype 
control IgG. Scale bar, 50 µm. (B) Membrane surface areas of 50 cells per sample were analyzed 
for three independent samples (n=3) using ImageJ software (version 1.49t). Values for each cell 
are shown in different models and the average surface area is marked with a solid line. ** 
indicates p value < 0.01. 
 
Furthermore, HAEC packing density was determined according to the microscopy 
images and reported as 66266 ± 15265, 63252 ± 7468, and 67798 ±12713 cells/cm2 for 
microporous membrane, collagen coating, and collagen matrix models, respectively. Although 
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HAEC size distribution pattern is different on the microporous membrane, collagen coating, and 
collagen matrix microenvironments, the average cells packing density is not changing 
significantly. Hence, we expected to get the same cell viability results in different models which 
correlates to the viability data presented in Fig. 10A. 
 
2.3.3 Expression of CAMs and MCP-1 on the endothelial cell surface 
The kinetic and magnitude of CAMs and MCP-1 expression on the HAEC surface was 
measured for control and TNF-α activated samples by direct immunofluorescence staining and 
detection by flow cytometry. Results are presented in Fig. 13 as ratio of the net mean fluorescent 
intensity (MFI) and percentage positive (PP) of cell population in activated samples to the control 
(media with no TNF-α stimulation). 
There was a low expression of VCAM-1 on unstimulated endothelial cells (data not 
shown), and a significant upregulation of VCAM-1 expression after 24 h TNF-α treatment (15.4-
fold increase compared to control). The PP of the cells population expressing VCAM-1 is not 
changing significantly after 6 h activation for both models. However, the MFI of the VCAM 
expression is increasing gradually between 6-18 h when it increases significantly after that up to 
24 h for both models. At 24 h stimulation by TNF-α, the MFI of VCAM-1 positive cells in the 2D 
model is significantly higher than cells in the 3D tissue model (2.3-fold, p < 0.01). 
ICAM-1 is expressed on normal endothelium in control samples (data not shown), but the 
expression is upregulated after stimulation by TNF-α with a time course similar to that of 
VCAM-1. Increase of ICAM-1 membrane expression PP reached a plateau after 6 h TNF-α 
activation. However, the MFI of ICAM membrane expression is increasing in both models. 
ICAM-1 membrane protein expression was detected to a lesser extent in the 3D tissue model than 
the 2D model at both early and late time points. It was shown that the MFI expression of ICAM-1 
protein were statistically significantly higher in HAEC treated with 24 h TNF-α in 2D models 
compared to the 3D tissue models (1.9-fold, p < 0.05). 
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Figure 13. HAEC membrane protein expression flow cytometry analysis of CAMs/MCP-1 in the 
2D and 3D models. For each sample, uniform population of the endothelial cells were gated using 
side versus forward scatter plots to exclude dead cells and debris. The Overton subtraction 
method was used to determine percentage positive (PP) and net mean fluorescent intensity (MFI) 
of the cells population compared to the isotype controls for each marker. Results are presented as 
mean fluorescent intensity (MFI) and percentage positive (PP) of each marker in activated 
samples normalized to the control samples (media with no TNF-α stimulation); n=3, MFI of 
HAEC ICAM expression is significantly higher in 2D models compared to the 3D tissue models 
after 6 h activation with TNF-α (* p < 0.05). 
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It is also worth noting that the increase in PP cells expressing VCAM-1 after activation is 
significantly higher than the positive cells for ICAM-1 membrane protein compared to the control 
samples. 
 PECAM-1 expression localized at cell–cell borders of HAEC confluent monolayers is not 
upregulated in response to TNF-α compared to the control samples without stimulation. No 
significant differences of PECAM-1 expression (MFI and PP) were observed on the cells surface 
between the 2D and 3D models which shows that TNF-α did not have effect on PECAM 
expression in both models over 24 h activation. 
 The expression of MCP-1 was observed on the cells surface with not a significant 
difference between the 2D and 3D models after activation. According to the flow cytometry 
results, moderate number of HAEC population has expressed MCP-1 after 6 h activation (16.1-
fold increase in PP), but with a weak intensity (1.4-fold increase in MFI). The increase of MCP-1 
membrane protein expression (both PP and MFI) reached a plateau after 6 TNF-α incubation 
when it remains unchanged till 24 h stimulation. 
 The data suggest that TNF-α increases the level of VCAM-1 and ICAM expression on 
the HAEC surface in both models. And the HAEC from the 2D models have a higher expression 
of the key CAMs intensity (MFI) and the same expression of MCP-1 associated with monocytes 
cell migration than the HAEC from the 3D tissue model after 24 h stimulation. 
 
2.3.4 Release of MCP-1 within the 3D tissue model 
The kinetic of MCP-1 release from the HAEC over 24 h time point in both the apical and 
basal side of the HAEC for the 2D and 3D models was measured by ELISA and shown in Fig. 14. 
The data demonstrate that HAEC had the highest release of MCP-1 in the apical and basal 
compartments of endothelium after 24 h TNF-α stimulation in both models with a significant 
difference between the 2D and 3D models at each activation incubation time point. 
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Figure 14. MCP-1 concentration (ng/ml) released from HAEC in the apical and basal of 
endothelium in 2D and 3D models for TNF-α activated (10 ng/ml) and control (normal condition) 
samples at different time points. Arrows show concentration elevation from control to activated 
condition. And ratio of total MCP-1 mass (ng) released from HAEC after treating with TNF-α (10 
ng/ml) to MCP-1 mass released in control samples (normal condition) in the 2D model compared 
to the 3D tissue model at different time points. Values are presented as mean ± SD; n=3, MCP-1 
concentration is significantly higher in activated samples compared to control (* p < 0.05). 
 35 
  
Although the final concentration of MCP-1 in the endothelial basal layer is shown to be 
identical in the 2D and 3D models, in fact a significant difference in the net release of MCP-1 is 
observed in the collagen matrix of the 3D tissue model compared to the HAEC basal layer in 2D 
model. After 24 h activation, HAEC released MCP-1 with 2.9 and 11.2–fold increase compared 
to the corresponding control samples in the 2D and 3D models, respectively. Accordingly, due to 
the sample concentrated in the collagen matrix, resulting in an abrogated release into the 
surrounding media, an earlier detection of MCP-1 release was expected from the 3D tissue model. 
As it is shown in Fig. 14, there is no significant difference in the MCP-1 concentration released to 
the basal layer of HAEC in the 2D model after 6 h TNF-α activation compared to the control 
sample. However, stimulating HAEC in the 3D tissue model for 6 h had a significant effect on 
MCP-1 release in the collagen matrix beneath the HAEC layer (9.5-fold, p < 0.01). 
Furthermore, the results display that the ratio of total MCP-1 mass released when HAEC 
were activated to the control samples increased significantly as the TNF-α incubation time was 
increasing in both models. Moreover, the normalized MCP-1 amount released is exhibited to be 
statistically significantly higher in the 3D tissue model compared to the 2D model starting at 6 h 
stimulation up to 24 h when the ratio was 1.6-fold higher in the 3D tissue model than 2D model 
(p < 0.05). Taken together, these results indicate that having the collagen matrix beneath the 
endothelium in the 3D tissue model had altered the cells behavior in producing MCP-1 before and 
after activation which will have an influence on monocytes migration later on. 
 
2.3.5 Monocytes adhesion and transendothelial migration 
Total number of monocytes that adhered and migrated across the endothelial cell layer 
for each model was determined by direct immunofluorescence staining and detection by flow 
cytometry. The percentage of monocytes that adhered to and migrated through the endothelium 
after 2 h is presented in Fig. 15. The results show that there are significantly more monocytes 
transmigration occurred in the 3D tissue model compared to the 2D model after 24 h of  
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Figure 15. Monocyte adherence and migration across the HAEC layer for each model in response 
to MCP-1 gradients for control and activated samples. HAEC were treated with 10 ng/ml TNF-α 
for 1 and 24 h. TNF-α treated 2D and 3D models and 3D tissue models incubated with an excess 
of MCP-1 neutralizing antibody (neutralizing Ab) were compared. Samples incubated with 
complete media without TNF-α was used as a negative control (NC). Human monocytes (1.5*105 
cells/cm2 in 0.5 ml media) were added on the apical layer of HAEC and the samples were 
incubated at standard conditions for 2 h. At the end of the incubation time, the top surface was 
rinsed and the number of monocytes that adhered on or migrated through the endothelium was 
determined. Values are presented as mean ± SD of the percent of attached and migrated 
monocytes normalized to the initial number of monocytes added to each well; n=3; # and * 
indicate p < 0.1 and 0.05, respectively, for change in percentage of adhered and migrated 
monocytes. 
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stimulation (2.2-fold, p < 0.1) and the negative control (NC) samples without TNF-α treatment 
(2.4-fold, p < 0.1), which shows the effect of different MCP-1 concentration gradient profile on 
monocytes migration. An increase in the number of monocytes that migrate across the endothelial 
layer for the 3D tissue model compared to the 2D model, indicates that MCP-1 influence is 
greater in the 3D tissue model, due to the MCP-1 haptotactic gradient. The greater number of 
monocytes for the HAEC in the 3D tissue model can be attributed to the difference in MCP-1 
within the collagen of the 3D tissue model compared to the free MCP-1 in the 2D model. 
We also studied the specificity of the MCP-1 gradient on the monocyte migration by 
neutralizing the available MCP-1 with MCP-1 antibody. The results show that there is a 
significant reduction in the number of monocytes adhered and transmigrated between the anti-
MCP-1 antibody-treated samples versus the 24 h activated samples (7.2-fold, p < 0.05). Our 
results clearly show that treatment with the MCP-1 antibody could significantly reduce MCP-1 
induced monocytes migration through the collagen matrices. 
 
2.4 Discussion 
In this study, an advanced 3D in vitro vascular tissue model was introduced as a novel 
tool to study the early cellular mechanisms involved in atherosclerosis plaque formation. Using 
this new model, the effect of MCP-1 concentration profile on monocytes migration was 
determined. The results supported our hypothesis that MCP-1 transport was different in the 3D 
tissue model than the traditional 2D microporous membrane model, which resulted in a difference 
in monocytes transendothelial migration between the two models. 
Expressed chemokines such as MCP-1 diffuses into the ECM where they can bind to the 
ECM proteins and maintain, so ECM proteins are important factors for immobilizing chemokines 
and preserving the profile [40]. Despite of this fact, the nature of the MCP-1 gradient and its 
effect on monocytes migration has been very difficult to assess in an in vivo setting and its 
mechanism is still not clear and is a very controversial area.   
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2D cell culture model is widely used to investigate the MCP-1 concentration gradient 
effect on monocytes migration. Endothelial cells are grown on a thin, microporous membrane, the 
MCP-1 is added to the aqueous media below the membrane, and monocytes are added to the 
apical surface of the endothelial layer. MCP-1 is added to both the apical and basal side of 
endothelium for chemotactic control [90]. Monocytes moved across the pores toward the MCP-1 
solution and transmigration of the cells was observed [88]. The number of transmigrated 
monocytes across the endothelial cell layer and the microporous membrane is counted for 
different concentrations of MCP-1 and different time points [92]. This model may not adequately 
predict in vivo cell behavior due to the lack of the third dimension which is an important factor in 
many physiological conditions. Interaction between cells and the below matrix and also the cell 
migration microenvironment condition are the most important issues that have to be considered in 
cell culture studies which are not achievable in 2D models. In order to address these issues, 
subsequent studies have proposed some alternatives as a development of 3D tissue models in 
laboratories [41, 100]. In this study, 3D tissue model is introduced as a tool to study monocytes 
transendothelial migration within the ECM. The 3D tissue model consisting of a type Ι collagen 
matrix would be a better experimental model to mimic the ECM as it is a major constituent of 
many tissues that make it useful for many model applications, and it can be obtained in a pure 
form without mixture of other bioactive ECM proteins which will simplify the experiment and the 
model [91]. It is more likely to have ECM below the endothelial layer, so the secreted 
chemokines such as MCP-1 and its corresponding profile can concentrated as a fluid phase or 
bound to the beneath matrix compound [41]. The 3D tissue model provides the added dimension 
that is important for the creation of a diffusive concentration gradient formed in the ECM, which 
is responsible for the control of many cellular mechanisms. Such a 3D tissue model can be used 
in vitro cellular model to construct cell-immunity model [100]. After passing across the 
endothelial layer monocytes can continue migration via chemoattractants [100] known as MCP-1 
[66] in the beneath space. 
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In this study, we showed that there were significant differences in HAEC response to 
TNF-α and monocytes transendothelial migration between the 2D and 3D models. Significant 
differences in HAEC response included the expression of CAMs and the trans-endothelial electric 
resistance in response to TNF-α stimulation. The HAEC from the 2D models had a greater 
expression of the key CAMs associated with monocytes cell migration than the HAEC from the 
3D tissue models. Significant differences in monocytes transendothelial migration between the 
2D and 3D model showed that overall there is greater transendothelial monocytes migration in the 
3D tissue model compared to the 2D model. An increase in the number of monocytes that migrate 
across the endothelial layer for the 3D tissue model compared to the 2D model indicates that 
MCP-1 influence is greater in the 3D tissue model, possibly due to the haptotactic influence, and 
that other factors may be driving cell migration in the 2D model.    
Findings from comparing the two models contribute to a better understanding of how 
cells behave in 2D versus 3D models and the development of improved experimental models. 
Proposed mechanisms can be used to target the MCP-1 involved during the inflammation with 
highly specific therapeutic strategies. A long term goal of our research group is utilizing the 
advanced 3D tissue model to test preventative and therapeutic interventions of atherosclerosis. 
Overall, the 3D tissue model is utilized in this project to characterize cellular adhesion 
molecules (CAMs) and to target one specific chemokine marker (MCP-1) that are critical 
participants in the transmigration of monocytes involved during the formation of the 
atherosclerosis lesion. The effect of MCP-1 local concentration gradients on monocytes migration 
is investigated using the 3D tissue model. HAEC behavior (the CAMs and the chemokine 
expression) and transport properties (MCP-1 release profile) is also studied between the 2D and 
the 3D models. Differences between two models characteristics, such as MCP-1 concentration 
gradients and cell behavior, and their effect on monocytes migration, i.e., the effect of diffusive 
gradients in a 3D environment compared to a 2D model, will help us to have a better 
understanding of underlying mechanisms in atherosclerosis. 
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In conclusion, we have shown that kinetics and the level of CAMs expression in the 2D 
model is different from the 3D tissue model which has an effect on monocytes adhesion and 
transmigration through the endothelial layer between the two models. This 3D tissue model 
consisting of a collagen matrix would be a better alternative experimental model to mimic the 
subendothelial ECM. Such a 3D tissue model provides the added dimension that is crucial for the 
creation of diffusive concentration gradients which is an important factor in many physiological 
conditions. So this 3D tissue model can be used as an effective tool for studying the monocytes 
transendothelial migration through the endothelial layer. The concentration gradient formed in the 
3D tissue model is distinctly different compared to the one in the 2D model, where the secreted 
factors from the endothelial cells dissolve quickly into the surrounding media. Furthermore, the 
3D tissue model provides a highly controllable micro-environment for investigating cellular 
interactions and responses [91]. Apart from this advantage, when focusing on the transmigration 
of monocytes, this matrix can also provide an area for monocytes to localize and differentiate into 
macrophages after the transendothelial migration [97]. This latter property of the 3D tissue model 
makes it applicable as a testing device for many diseases like atherosclerosis.  
Many questions still remain about the expression of MCP-1 from endothelial layer and its 
concentration profile in subendothelial tissue. More studies in this area will lead to the 
development of an improved in vitro model that exhibits native characteristics of in vivo in order 
to study transendothelial monocytes migration associated with MCP-1 profile and inflammatory 
conditions. Furthermore, as the next phase of this research, we expect utilizing the developed 3D 
tissue model to develop a second generation mathematical model that describes MCP-1 transport 
within the 3D model, which will include a source term of MCP-1 production from the HAEC in 
response to TNF-α and the binding reaction of MCP-1 to the collagen matrix. Validating the 
mathematical model by comparing the obtained numerical results to the experimental 
measurements of MCP-1 in the 3D tissue model and determining any correlation to monocytes 
migration would also be conducted. With the completion of ongoing future phases, an advanced 
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in vitro tissue model will be developed and can be used to study inflammation in atherosclerosis-
associated monocyte migration diseases. 
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CHAPTER 3 
 
 
A Mathematical Model to Describe the Release of Monocyte Chemoattractant Protein-1 
from Human Aortic Endothelial Cells and the Transport through a Three-Dimensional 
Collagen Matrix 
 
3.1 Introduction  
Atherosclerosis is an inflammatory disease that is initiated by the accumulation of lipid 
substances in the subendothelial layer of major arteries and followed by adhesion and 
transmigration of monocytes and lymphocytes to the extracellular matrix (ECM) [4-12]. The end 
state of the monocytes after transendothelial migration is dependent on many factors, such as the 
specific tissue involved in the process, the type of stimulus, and the formation of chemotactic 
concentration gradients in the tissue. The adhesion and transmigration process involves several 
steps and is mediated by bioactive molecules named chemotactic cytokines (chemokines) [17, 36-
40]. Chemokines can form concentration gradients that are free (fluid phase) or bound 
(immobilized) components [41-48] in the ECM. Monocyte chemoattractant protein-1 (MCP-1) is 
expressed highly in atherosclerotic lesions in the early stage of atherosclerosis and facilitates 
monocytes trafficking across the endothelial cell layer [53-55, 57-59]. MCP-1 recruits monocytes 
to sites of tissue injury, infection, and inflammation via its concentration gradient [63-67, 89]. 
The absence of MCP-1 in a murine model is also shown to decrease the formation of 
atherosclerotic lesion [61, 62].
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These findings suggest that MCP-1 plays an important role in atherosclerosis formation. 
Having a better understanding of the underlying mechanisms involved in the role of MCP-1 in 
controlling monocytes migration will help to identify targets to prevent the atherosclerotic plaque 
formation.  
Previous studies have used two-dimensional (2D) experimental systems to investigate the 
effect of chemokines on monocyte migration [65, 88-90]. Traditional 2D systems may not be 
suitable predictors of what occurs in more complex three-dimensional (3D) systems, like those 
within the human body [91]. The 2D cell culture model is adequate for showing a response of 
monocytes to a chemokine that has formed a concentration gradient of free proteins across the 
endothelial cell layer; however, the 2D system cannot be used to examine bound chemokine 
concentration gradients that form within the tissue in vivo [17, 36, 40, 44, 47, 48, 71, 72, 93-96]. 
In the 2D system, endogenous MCP-1 released by the cells to the surrounding liquid media is 
diluted, quenching the chemoattractant effect.  
A better alternative experimental model is a 3D model consisting of a matrix to mimic 
the subendothelial ECM. The major advantage of the 3D model is that the third dimension 
provides the supplementary space that is significant for the creation of diffusive concentration 
gradients in the ECM. During analysis of a 3D system consisting of a collagen matrix without 
cells, a binding reaction between MCP-1 and the collagen matrix was discovered, which shows 
that in addition to a gradient of free MCP-1, a gradient of collagen-bound MCP-1 may be formed 
in the collagen matrix as well [98]. Due to the low concentrations (pg-ng per ml range), there is 
no technique available to quantify such gradients inside the collagen matrix.  
In this study, a three-dimensional (3D) in vitro vascular tissue model was created in order 
to provide the added dimension required to form diffusive concentration gradients of endogenous 
MCP-1. The 3D tissue model consists of Human Aortic Endothelial Cells (HAEC) grown on the 
surface of a collagen matrix, to mimic the vascular endothelium and the subendothelial ECM, 
respectively. The main objective of this study was to derive a mathematical model to predict the 
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MCP-1 concentrations at various time points and locations within the collagen matrix of the 3D 
model. The unsteady-state transport model includes a source term to describe MCP-1 production 
from the HAEC and a binding reaction term to describe the interaction of MCP-1 with the 
collagen matrix. The release of MCP-1 from the HAEC in the 3D model, under normal cell 
culture conditions and in response to an inflammatory stimulus was determined. Tumor necrosis 
factor-α (TNF-α) was used as an immunologically activator to mimic inflammation that occurs in 
the early stages of atherosclerosis.  
The mathematical model analysis will provide new information about formation of the 
free and bound MCP-1 concentration profile in the ECM. Then, the concentrations profile can be 
related back to the monocytes transendothelial migration associated with inflammation involved 
in the early stages of atherosclerosis. 
 
3.2 Methods 
3.2.1 Cell culture 
Human Aortic Endothelial Cells (HAEC) and endothelial cell basal medium were 
purchased from PromoCell, Heidelberg, Germany. HAEC were cultured in 75 cm2 flasks and 
incubated at standard conditions (37 °C, humidified atmosphere of 5% CO2) and used at 90% 
confluence. 
 
3.2.2 Preparation of the 3D in vitro vascular tissue model 
The 3D in vitro tissue model was constructed in 12-well format ThinCert Transwells® 
(Greiner Bio-one, Frickenhausen, Germany) as described in the previous protocols [97, 98]. 
Briefly, the collagen matrix was coated with fibronectin (Biomedical Technologies, Stoughton, 
MA) and seeded with HAEC (7.5*104 cells/cm2). The cells were incubated and used for 
experiments one day post-confluence. A schematic diagram of the 3D tissue model is shown in 
Fig. 16A. 
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Figure 16. (A) Schematic side view of 3D in vitro tissue model containing collagen matrix to 
represent an extracellular matrix (ECM) and an endothelium on top. The model was used to 
describe the release of monocyte chemoattractant protein-1 (MCP-1) from Human Aortic 
Endothelial Cells (HAEC) and the subsequent diffusion and transport through the ECM. (B) One 
dimensional unsteady-state axial diffusion in cylindrical coordinate model used to describe the 
diffusion of released MCP-1 in the 3D tissue model. 
 
3.2.3 MCP-1 and collagen binding reaction 
 The rate constant for the reaction between MCP-1 and collagen was determined 
experimentally, by adding a known concentration of recombinant human CCL2/MCP-1 (R&D 
Systems, Minneapolis, MN) to a collagen matrix and measuring the amount that binds to the 
collagen after set incubation times. Samples of the collagen matrix were prepared in a solid 96-
well plate (Greiner Bio-one, Frickenhausen, Germany). Solutions of MCP-1 at the following 
concentrations were prepared in complete medium (endothelial basal media with growth factors, 
PromoCell) and added to the top of the collagen matrix: 10, 25, and 50 ng/ml. The samples were 
incubated at culture conditions for 1, 6, 12, and 24 h to allow for MCP-1 to bind to the collagen 
matrix. After incubation, the complete media was collected and the collagen matrix was washed 
five times with the complete medium to ensure that all free MCP-1 is removed completely from 
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the collagen matrix. For each wash, fresh complete medium was added to the top of the collagen 
matrix and incubated for 1 h. The concentration of MCP-1 in the collected samples was measured 
by a commercially available human MCP-1 ELISA kit (BD Biosciences, San Jose, CA), 
following the manufacturers protocol. Based on the measured MCP-1 concentrations and having 
the collagen matrix volume calculations (manuscript in review), MCP-1 concentration in the 
collagen matrices were determined. 
 
3.2.4 The production rate of MCP-1 from the endothelial cells during the growth phase 
 To determine the production rate of MCP-1 from HAEC during the growth phase, 
samples were analyzed for MCP-1 release after 2, 4, and 6 days post seeding HAEC on the 
collagen matrices during endothelium growth phase. To measure MCP-1 release from HAEC in 
the 3D tissue models, media from both the apical and the basal compartments of the endothelium 
were collected and stored separately at -20 °C. To quantify MCP-1 concentration in the matrix, 
collagen matrices were digested by using collagenase D (Roche Applied Science, Indianapolis, 
IN). Briefly, collagenase D was added on the collagen matrices and incubated at culture 
conditions for 1-2 h to digest the matrices. Digested samples were centrifuged and the cell-free 
supernatants were stored at -20 °C. MCP-1 concentration was measured in the collected solutions 
using a human MCP-1 ELISA kit following the manufacturer’s protocol and the MCP-1 
concentration in the collagen matrices were determined. 
 
3.2.5 The production rate of MCP-1 from the endothelial cells during the activation phase 
 To determine the MCP-1 production rate, the total concentration of MCP-1 released at 1, 
6, 12, 18, and 24 h before and after activation was determined. MCP-1 concentration in the apical 
and basal layer of HAEC were measured by ELISA, using the manufacturer’s recommended 
protocol as described in section 3.2.4.  
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3.2.6 Statistical analysis 
MCP-1 concentrations are reported as mean ± standard deviation (SD) of triplicate 
samples. Student’s t-test was used to determine if there are significant differences in the MCP-1 
measured concentrations among the pairs. A p value of < 0.05 is considered significant. 
 
3.3 Model development 
The release of MCP-1 from the endothelial cell layer and subsequent diffusion through 
the collagen matrix was modeled as one dimensional unsteady-state diffusion in cylindrical 
coordinates, as shown in Fig. 16B. The cross sectional area and pore size of the membrane well 
used in this study were 1.13 cm2 and 8.0 µm, respectively. The equation of continuity, along with 
experimental data, was used to derive a mathematical model that can be used to estimate MCP-1 
concentration gradients within the 3D tissue model. The concentration gradients within the 3D 
tissue model are formed by diffusion of released MCP-1 from the endothelial cell surface into the 
collagen matrix through the bottom chamber. The binding reaction between MCP-1 and the 
collagen matrix can be displayed as: 
F•M + S             B•M 
Where F•M is the free MCP-1, S is a binding site in the collagen matrix, and B•M is a bound 
MCP-1 to the collagen binding site. Diffusion of MCP-1 in the 3D tissue model was modeled as 
unsteady-state diffusion in one dimension [44] as shown in Fig. 16. The equation of continuity 
was used to derive a mathematical model that can be used to estimate MCP-1 concentration 
gradients within the 3D tissue model. 
 
3.3.1 Assumptions 
The following assumptions were made to simplify the equation of continuity:  
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1) Solutions above and below the collagen matrix were well-mixed, so there are no MCP-
1 concentration gradients in the apical side of endothelium and below the membrane 
compartment. In order to test the validity of this assumption, the value of diffusion coefficient of 
MCP-1 in the water was compared to the diffusion coefficient obtained in the previous study [44]. 
MCP-1 diffusion coefficient in water was estimated previously [47]. Diffusion coefficient of 
bioactive molecules that are in the same family of MCP-1 was also reported by Fluery et al [48]. 
It was found that MCP-1 diffusion in water is faster than in the collagen matrix. Diffusion 
coefficients of molecules with various molecular weights also showed higher values in normal 
compare to free diffusion in water [49]. This finding suggests that MCP-1 diffuses more quickly 
in the top and bottom reservoirs than in the collagen matrix.  
2) The MCP-1 concentration at the top surface of the collagen matrix is equal to the 
concentration of the top reservoir, and the MCP-1 concentration at the bottom surface is equal to 
the concentration of the bottom reservoir. 
3) The volumes of the top and bottom reservoirs are constant. 
4) The effective diffusive coefficient of MCP-1 is constant and not a function of 
concentration, because the MCP-1 concentration is very small (in pg/ml - ng/ml level range). 
5) The change in the MCP-1 concentration has a negligible effect on the total 
concentration of the system, since the MCP-1 concentration range is very small (in pg/ml - ng/ml 
level). So, the total concentration is constant. 
6) Binding reaction rate depends only on the concentration of MCP-1. Since the 
concentration of collagen is significantly higher than MCP-1 concentration level range (pg/ml - 
ng/ml), it is assumed that the collagen concentration is not changing significantly compare to the 
MCP-1 concentration. Thus, the concentration of collagen is considered as a constant value.   
7) The migration of MCP-1 through the collagen matrix is due to the diffusive 
concentration gradients only not convective mass transfer, since the system is static. 
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8) The diffusion gradient is assumed to be only in z-direction, the perpendicular direction 
to the endothelial layer. There is no radial (r-direction) or angular (θ-coordinate) MCP-1 
concentration gradient, due to the system symmetry in the collagen matrix cylinder shape model.   
9) The effect of MCP-1 mass transfer across the thin, polycarbonate membrane is 
negligible in comparison with the diffusion through the collagen matrix, because (i) the thickness 
of the membrane is significantly less than that of the collagen matrix and (ii) the pore size of the 
membrane is few orders of magnitude larger than the size of MCP-1 molecules (4 nm diameter). 
10) Binding of MCP-1 to the wall of the membrane well is neglected. The system is 
incubated with basal media containing endothelial growth factors overnight prior seeding the 
cells. The endothelial growth factors include fetal calf serum (FCS) that can act as a blocking 
protein for the non-specific bindings in the system.   
11) The curvature of the top surface of the collagen matrix due to meniscus formation 
during the gelation process is neglected. Because the membrane radius is significantly higher than 
the collagen thickness (1.8-fold), the resulting curvature can be neglected. 
 
3.3.2 Governing equations 
By applying the assumptions, listed in section 3.3.1, to the equation of continuity, the 
mathematical model becomes: 
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Where DM׀C is the diffusive coefficient of MCP-1 through the collagen matrix (0.108 mm2/hr) 
[44]; RF.M is the reaction rate term; CF.M is the mass concentration of free MCP-1 in the collagen 
matrix; t is time, and z is the distance from the top surface of the collagen. The reaction rate term 
is used to describe the rate of conversion of free MCP-1 in the collagen matrix to the bound 
MCP-1 form. According to our previous study, there is no loss of MCP-1 during the current 
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experimentation time period according to our previous study [46]. The consumption rate of MCP-
1 is shown in Eq. 2. 
                                                                 tzCKtzR MFbMF ,, ..                                                  Eq. 2 
In Eq. 2, RF.M is the rate term; CF.M is the concentration of free MCP-1 in the collagen matrix; Kb 
is the rate constant for the binding; α is the order of the reaction; t is time; and z is the distance 
from the top surface of the collagen (Fig. 1A).  
By substituting Eq. 2 into Eq. 1, the model equation becomes: 
                                   
   
 tzCK
z
tzC
D
t
tzC
MFb
MF
CM
MF ,
,,
.2
.
2
. 










                                  Eq. 3 
This equation determines the concentration of free MCP-1 within the 3D tissue model at various 
time points and locations. 
The equation of continuity was used to develop a mathematical model that represents the 
bound MCP-1 concentration profile in the collagen matrix. As opposed to free MCP-1, which 
could diffuse through the matrix, bound MCP-1 is assumed to be fixed inside the collagen matrix, 
due the binding of free MCP-1 and the collagen binding site. Therefore, the equation of 
continuity for bound MCP-1 contains the accumulation and the rate of production terms and is 
shown in Eq. 4. 
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                                                            Eq. 4 
In Eq. 4, CB.M is the mass concentration of bound MCP-1 in the collagen matrix as a function of 
time and location in the z-axis, and RB.M is the MCP-1 binding reaction rate term. The production 
rate of bound MCP-1 is equal to the negative value of the consumption rate of free MCP-1, as 
shown below in Eq. 5, 
                                                         tzCKtzRtzR MFbMFMB ,,, ...                                       Eq. 5 
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Combing Eq. 4 and 5, the mass balance equation of the bound MCP-1 in the collagen matrix 
becomes: 
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                                            Eq. 6 
In order to solve Eq. 3 and 6, initial conditions for CF.M and CB.M and boundary conditions for CF.M 
are required. 
 
3.3.3 Initial and boundary conditions 
To solve Eq. 3 and 6 for the 3D tissue model, the initial and boundary conditions are 
shown in Eq. 7 and 8, respectively. 
Initial conditions:                
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Boundary conditions: 
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                Eq. 8 
For the initial conditions shown in Eq. 7, Ci.F.M and Ci.B.M are the initial concentrations of free and 
bound MCP-1 in the collagen matrix before endothelial cell activation, respectively. For the 
boundary conditions shown in Eq. 8, A is the surface area of the top or bottom surface of the 
collagen; V is the volume of the top and bottom chambers; δ is the thickness of the collagen 
matrix; and Rp.a is the production rate of MCP-1 from the endothelial cells (source term) at each 
time point of activation. 
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3.3.4 Free and bound MCP-1 concentration profile during the endothelial cells growth 
phase 
The amount of MCP-1 released from the HAEC in the 3D tissue model during cell 
proliferation was measured in order to determine the initial concentration profile of free (Ci.F.M) 
and bound (Ci.B.M) MCP-1 in the collagen matrix (prior to activation). The equations of continuity 
(Eq. 3 and 6) were used to develop a mathematical model that represents the MCP-1 
concentration gradient in the collagen matrix during the growth phase. For the growth phase, the 
initial concentration of MCP-1 was zero at time = 0, when HAEC were seeded on top of the 
collagen matrix.  
Initial conditions: 
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The boundary conditions described in the activation phase were modified to the following. 
Boundary conditions: 
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                    Eq. 10 
In the boundary conditions shown in Eq. 10, Rp.g is the production rate of MCP-1 from the 
endothelial cells during the growth phase. 
 
3.3.5 The order of the reaction and the reaction rate constant for MCP-1 and collagen 
binding 
The system was modeled as a batch reactor, and the differential method was used for the 
rate analysis, as shown in Eq. 11. 
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                                                                 
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. ,                                                Eq. 11 
The above differential rate model (Eq. 11) was used in combination with the Eq. 2 and the 
experimental data obtained from section 3.2.3 to determine the order of the reaction (α) and the 
reaction rate constant (Kb) experimentally. 
 
3.4 Numerical solution 
 The resulting partial differential mathematical equations were solved in MS-Excel 
(version 2010) with Visual Basic for Applications (VBA) using the Crank-Nicolson numerical 
method. 
 
3.5 Empirical solution 
The numerical results obtained from solving the differential mathematical equations were 
fed in MATLAB software (version 8.3) and a curve fitting tool was applied to the data to 
determine the best 3D curve fit for MCP-1 concentrations at different location within the collagen 
matrix and different stimulation time point. Obtained equation of MCP-1 concentrations as a 
function of location and time was integrated over the total location range in the matrix (δ) and the 
incubation time point to calculate the expected total MCP-1 mass in the collagen matrix at each 
time point. 
 
3.6 Results 
3.6.1 MCP-1 and collagen matrix interaction 
Existence of an irreversible binding reaction between MCP-1 and collagen matrix was 
demonstrated in our previous study (manuscript in review). Briefly, human recombinant MCP-1 
(50 ng/ml) was added on top of the collagen matrix and the plate was incubated for 24 h allowing 
MCP-1 to diffuse in the matrix. Samples were washed ten times in order to remove the free MCP-
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1 from the matrices. The amount of free MCP-1 in the solution was measured and a mass balance 
equation (Eq. 12) was used to determine the amount of remaining MCP-1 in the collagen matrix 
after each wash. Obtained results showed that the total MCP-1 concentration in the collagen 
matrix decreased gradually with each wash until the fifth wash where there was no significant 
change in MCP-1 concentration in the collagen matrix was observed for the remaining washes.  
matrix
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    Eq. 12 
In Eq. 2, Cj.matrix is the total MCP-1 concentration in the collagen matrix at the end of each 
washes; Ci is the MCP-1 concentration initially added on top of the collagen matrix; CF.M.j is the 
free MCP-1 concentration in the top solution at each wash; n is the number of washes; Vtop is the 
volume of the solution on top of the collagen matrix, and Vmatrix is the volume of the collagen 
matrix.  
In the current study, we have used different initial concentrations of MCP-1 (10, 25, and 
50 ng/ml) and incubated the samples for 1, 6, 12, and 24 h time points to investigate the kinetic 
mechanism behavior of the binding reaction as a function of the initial concentration and the 
reaction time. For each initial concentration, total MCP-1 concentration in the collagen matrices 
were calculated at each incubation time point and after each wash using the mass balance (Eq. 12) 
for the total number of five washes and results are represented in Fig. 17.  
The results show that total MCP-1 concentration in the collagen matrices is highly 
dependent on the MCP-1 concentration initially added on the collagen matrices and the matrices 
incubation time points. It is demonstrated that at low initial concentrations, such as 10 ng/ml, 
there is no significant increase in the total MCP-1 concentration in the collagen matrix when the 
incubation time is increasing from 1 to 6 h. The average MCP-1 concentration in the collagen 
matrix is increasing gradually as the incubation time increases to 24 h where there is a significant 
change compared to the results after 1 h (2.4-fold, p < 0.01). In contrast to 10 ng/ml, when 25 
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ng/ml MCP-1 was used initially, there is a significant increase in the total MCP-1 concentration 
in the matrices between 1 to 6 h (1.6-fold, p < 0.01) where there is no significant change in the 
total MCP-1 concentration after that up to 12 h. However, increasing the incubation time from 6 
to 24 h, has increased the total MCP-1 concentration in the matrix significantly (1.2-fold, p < 
0.05). Increasing the initial concentration to 50 ng/ml has increased the total MCP-1 
concentration in the collagen matrices, significantly, compared to 25 ng/ml results at each time 
point (p < 0.01). Having 50 ng/ml initial concentration and increasing the incubation time from 1 
to 6 h, has increased the MCP-1 concentration in the matrix significantly (1.4-fold, p < 0.05) 
where there is no significant change in the total concentration after that up to 24 h.  
Having the concentration of free MCP-1 at the end of each incubation time and after each 
wash, the concentration of free MCP-1 in each system (total sample volume) after each 
incubation time period was determined. Furthermore, the concentration of bound MCP-1 in the 
system was calculated based on the data obtained from Fig. 17. The concentration of free and 
bound MCP-1 in the system is reported for each initial concentration at different incubation time 
point and represented in Fig. 18.  
It was demonstrated that at low initial concentrations, such as 10 ng/ml, there is no 
reaction between collagen and MCP-1 up to 12 h and the average total MCP-1 concentration in 
the collagen matrix is increasing gradually as the incubation time increases to 24 h when there is 
a significant increase in the concentration of bound MCP-1 compared to 1 h (5.5-fold, p < 0.05). 
However, with increasing the initial concentration to 25 ng/ml, collagen and MCP-1 forms an 
irreversible binding even after short period of incubation time, such as 1 h. Incubating the 
collagen matrices for another 5 h has elevated the concentration of bound MCP-1 in the system 
significantly (1.7-fold, p < 0.05). The concentration of bound MCP-1 in the system has not been 
changed significantly after 6 h up to 24 h.  
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Figure 17. The concentration of MCP-1 (ng/ml) in the collagen matrix at the end of each 
incubation time and after each washes. Collagen matrices were pretreated with 10, 25, and 50 
ng/ml MCP-1 and incubated for 1, 6, 12, and 24 h. The concentration of free MCP-1 in the top 
solution was measured by ELISA and the mass balance equation was used to determine the 
remaining total MCP-1 concentration in the collagen matrices (as described in Materials and 
Methods). Values are presented as mean ± SD; n=3. 
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Figure 18. The concentration of free and bound MCP-1 (ng/ml) in the system for three different 
initial MCP-1 concentrations (10, 25, and 50 ng/ml) at the end of each incubation time. Collagen 
matrices were pretreated with 10, 25, and 50 ng/ml MCP-1 and incubated for 1, 6, 12, and 24 h. 
The concentration of free MCP-1 in the top solution was measured by ELISA and the mass 
balance equation was used to determine the remaining total MCP-1 concentration in the collagen 
matrices (as described in Materials and Methods). Values are presented as mean ± SD; n=3. 
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It is also shown that incubating samples for different time periods does not have a 
significant effect on the concentration of bound MCP-1 in the system and that the concentration is 
similar to the case where 25 ng/ml MCP-1 was used initially. Taken together, these results clearly 
show that the collagen MCP-1 binding sites in the collagen matrices is saturated using the initial 
MCP-1 concentration of 25-50 ng/ml.  
 
3.6.2 Determining the order of the reaction and the reaction rate constant for MCP-1 and 
collagen binding 
The reaction rate constant and order of the reaction was determined experimentally by 
measuring the initial rate of reaction for various initial MCP-1 concentrations applied to the 
collagen matrix, as shown in Fig. 19. The slope and intercept of the line shown in Fig. 19 are the 
order of the reaction (α) and natural logarithm of reaction rate constant (ln Kb), respectively.  

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α = 0.98 ≈ 1, Kb =  0.26  hr-1 
 
3.6.3 MCP-1 kinetics from HAEC in the 3D tissue model in the growth phase and in 
response to TNF-α 
The kinetic profile of MCP-1 release from the 3D tissue model was determined by 
measuring the total concentration of MCP-1 released during the growth phase and over a 24 h 
time period activation with adding 10 ng/ml TNF-α. As shown in Fig. 20, total MCP-1 production 
from the HAEC increases significantly as the incubation time increases. The release follows a 
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linear trend and is used to determine the production rate of MCP-1 during the growth and 
activation phases (Table 2).  
 
 
 
Figure 19. Initial binding reaction rate of free MCP-1 as a function of free MCP-1 concentration 
in the system. Three different MCP-1 concentrations (10, 25, and 50 ng/ml) were added on the 
cell-free collagen matrices and incubated for 1, 6, 12, and 24 h. The concentration of free MCP-1 
in the top solution was measured by ELISA and the total free MCP-1 concentration in the system 
was determined for different MCP-1 initial concentrations and different incubation time points. 
Reaction rate was calculated for each initial concentrations and plotted as a function of free MCP-
1 concentration that was added initially to obtain the order of the reaction and reaction rate 
constant experimentally. Values are presented as mean; n=3. 
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Figure 20. The total concentration of MCP-1 (ng/ml) released from HAEC in the system for the 
growth and activation phases. HAEC were seeded on the collagen matrix and the concentration of 
MCP-1 in the samples were measured by ELISA every 2 days by the end of 6 day when the cells 
were confluent (growth phase). Then, HAEC were treated with 10 ng/ml TNF-α and sample were 
incubated for 1, 6, 12, 18 and 24 h at standard conditions to measure the MCP-1 release at each 
activation time point. The ctrl line demonstrated the total MCP-1 released for the control samples 
incubated with complete media without TNF-α. Values are presented as mean ± SD; n=3. 
 
3.7 Numerical results 
3.7.1 MCP-1 concentration gradients in the 3D tissue model at the end of HAEC growth 
phase 
As it was shown in Fig. 18, there is no bound MCP-1 in the concentrations as low as the 
measured MCP-1 concentration in the collagen matrices in the growth phase during 6 days post 
seeding HAEC on top of the collagen matrices. Therefore, the unsteady-state one dimensional 
mathematical model of continuity equation was solved for the free MCP-1 in the collagen matrix 
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with the corresponding initial and boundary conditions. Free MCP-1 concentration profile is 
shown in Fig. 21 as a function of distance from top surface of the collagen matrix. 
 
Table 2. HAEC production rate of MCP-1 mass concentration during the growth and activation 
phases. 
 
 
 
 
Figure 21. Concentration profile of free MCP-1 (CF.M) in the collagen matrix of the 3D tissue 
model at 6 days post seeding HAEC on top of the collagen matrix in the end of growth phase, 
predicted by the mathematical model. 
 
It is shown that the highest concentration of free MCP-1 is at z = 0 where there is a 
production source of MCP-1 at endothelium. The free concentration is decreasing gradually up to 
the bottom surface of the collagen matrix where there is a microporous membrane separating the 
collagen matrix from the bottom chamber.   
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3.7.2 MCP-1 concentration gradients within the 3D tissue model during the activation phase 
A second-generation mathematical model that describes MCP-1 transport within the 3D 
tissue model includes a source term of MCP-1 production from the HAECs in response to TNF-α 
and the binding reaction of MCP-1 to the collagen matrix. The updated mathematical model 
equations used to describe the transport of the free and bound form of MCP-1 in the collagen 
matrix were solved with the two new terms of Rs and Kb, described from the previous sections. 
The concentration profiles of free and bound MCP-1 in the collagen matrix, as determined by the 
mathematical model, are shown in Fig. 22.  
The developed mathematical model gives a better prediction of the concentration profiles 
within the vascular tissue model containing the HAEC. The model predicts the increase of MCP-1 
concentration (both free and bound) with time, due to the release of MCP-1 from the HAEC in 
response to TNF-α activation. The second-generation model with the experimentally determined 
binding rate kinetics shows lower concentrations of bound MCP-1 in the system, compared to 
previous predictions [98]. However, the concentration of bound MCP-1 remains higher than that 
of the free MCP-1 after 12 h and overcomes the gradient of free MCP-1 as the time passes. This 
finding further substantiates that, apart from the gradient of free MCP-1, the gradient of bound 
MCP-1 is another potent factor that may mediate monocyte transendothelial migration. 
 
3.8 Empirical results 
MATLAB software curve fitting tool was used to fit the obtained numerical data for the 
1, 6, 12, and 18 h to a 3D plane presenting the free and bound MCP-1 concentration as a function 
of location in the matrix and the incubation time. Polynomial curve with order of 3 and 2 in 
respect to z and t was selected and the empirical equation and plot for free and bound MCP-1 
concentrations were obtained. The free and bound MCP-1 concentration as a function of location 
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and incubation time are demonstrated in Fig. 23. The relation between each concentrations, 
location and time is represented in Eq. 15 with the constants listed in Table 3.  
 
 
Figure 22. Concentration profiles of free (CF.M) and bound (CB.M) MCP-1 in the collagen matrix of 
the 3D tissue model, predicted by the mathematical model containing a source term to describe 
MCP-1 production from the HAEC and a binding reaction term to describe the interaction of 
MCP-1 with the collagen matrix. 
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Figure 23. Concentration profiles of free (CF.M) and bound (CB.M) MCP-1 at each time point and 
location in the collagen matrix of the 3D tissue model, predicted with MATLAB curve fitting 
tool.  
 
𝐶𝑀 = 𝑎 + 𝑏𝑡 + 𝑐𝑧 + 𝑑𝑡
2 + 𝑒𝑡𝑧 + 𝑓𝑧2 + 𝑔𝑡2𝑧 + ℎ𝑡𝑧2 + 𝑖𝑧3      𝑅2 = 0.99  Eq. 15 
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Table 3. Constants obtained from fitting the numerical data to the polynomial plane curve. 
 
 
Numerical results for the selected time points (1, 6, 12, and 18 h) was used for curve 
fitting purposes. Free and bound MCP-1 concentrations obtained for 24 h incubation time point 
was used as a validation for Eq. 15 with the constants listed in Table 3. Therefore, two separate 
locations in the collagen matrix was selected and the concentrations of free and bound MCP-1 
was calculated at the selected positions at 24 h incubation time point using Eq. 15 and Table 3 
constants. Obtained data are listed in Table 4 along with the numerical values and the absolute-
average-percentage deviation (%AAD) of the numerical and empirical values are reported.  
 
Table 4. Comparison between the numerical and empirical free and bound MCP-1 concentration 
at two different locations in the matrix after 24 h stimulation. 
 
 
Moreover, the concentration equation was integrated over the total location range in the 
matrix (δ) and the incubation time point to calculate the expected total MCP-1 in the collagen 
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matrix at each time point. The results and a comparison between the experimental and empirical 
results are shown in Table 5. 
Table 5. Comparison between total MCP-1 in the collagen matrix at two different time points 
obtained from experiments and the empirical equations (Eq. 15). 
 
 
3.9 Discussion  
Acute and chronic inflammation responses direct the recruitment of leukocytes into the 
affected tissue. After adhesion of these immune cells on top of the activated endothelium, they 
are directed to the site of injury by chemokine concentration gradient. Specific chemokine 
profiles dictate migration of different leukocytes at the site of inflamed tissue. Expressed 
chemokines such as MCP-1 diffuses into the extracellular matrix (ECM) where they can bind to 
the ECM proteins and maintain, so ECM proteins are important factors for immobilizing 
chemokines and preserving the profile [40]. This concentration profile coordinates the cell 
migration and trafficking at the site of inflammation. However, the nature of these profiles has 
been difficult to determine in vivo systems.  
A 3D in vitro vascular tissue model, consisting of human aortic endothelial cells (HAEC) 
grown on the surface of a collagen matrix, was developed in this study to investigate MCP-1 
release within a 3D environment. The 3D tissue model provides the added dimension that is 
required for the creation of concentration gradients, along with cellular movement and 
interactions created by such gradients.  
During analysis of the system, a binding reaction between MCP-1 and the collagen 
matrix was discovered, which shows that in addition to a gradient of free MCP-1, a bound 
gradient may be formed in the collagen matrix as well. 
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The main objective of this study was to develop a mathematical model that can be used to 
predict the MCP-1 concentration gradients in the collagen matrix of a 3D tissue model. The 
unsteady-state transport model includes a source term to describe MCP-1 production from the 
HAEC and a binding reaction term to describe the interaction of MCP-1 with the collagen matrix. 
The release of MCP-1 from the HAEC in the tissue model, under normal culture conditions and 
in response to TNF-α, was determined at various time points over a 24 h period. The MCP-1 
release profile was used to derive the source term of MCP-1 production of the HAEC in the 
mathematical model.  
The binding reaction expression and rate constant were determined experimentally by 
measuring the initial rates of reaction for various MCP-1 concentrations applied to a collagen 
matrix without cells. The initial concentrations of MCP-1 included in this study for determining 
the order of the reaction and the reaction rate constant were 10, 25, and 50 nanogram per milliliter 
that were physiologically relevant, and were selected based on in vivo and in vitro experiments 
that measured the release of MCP-1 from cells [99, 101-109] and the use of MCP-1 to direct cell 
migration [103, 110-114]. 
The mathematical model indicates that the concentration gradients of both free and bound 
MCP-1 are formed inside the collagen matrix. The model predicts the increase of MCP-1 
concentration (both free and bound) with time, due to the release of MCP-1 from the HAECs in 
response to TNF-α activation. The concentration of bound MCP-1 remains higher than that of the 
free MCP-1 after 12 h and overcomes the gradient of free MCP-1 as time passes.  
The model further substantiates that apart from the gradient of free MCP-1, the gradient 
of bound MCP-1 is another potent factor that may mediate monocyte transendothelial migration. 
The mathematical model can be used to provide new information about the relationship between 
MCP-1 concentration gradients and monocyte transendothelial migration associated with 
inflammation.
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CHAPTER 5 
 
 
Conclusions and Future Work  
 
In this study, an advanced three-dimensional (3D) in vitro vascular tissue model was 
introduced as a novel tool to study the mechanisms occurring within the subendothelial 
extracellular matrix (ECM) during atherosclerosis. The 3D tissue model was utilized in this 
project to characterize cellular adhesion molecules (CAMs) and chemotactic cytokines 
(chemokines) that are critical participants in the transmigration of monocytes during the 
formation of the atherosclerotic lesion. These proteins can be potent therapeutic targets for the 
treatment and prevention of the inflammatory process associated with diseases like 
atherosclerosis. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that plays a major 
role in monocytes trafficking across the endothelial layer, and MCP-1 concentration gradients in 
the ECM are crucial in directing monocytes to the site of inflammation [53, 54, 63, 66].  
The 3D tissue model consists of a collagen matrix to mimic the ECM, which provides the 
added dimension for the creation of a diffusive concentration gradient responsible for the control 
of many cellular mechanisms. In this study, human aortic endothelial cells (HAEC) were grown 
on the surface of the collagen matrix to investigate MCP-1 release from HAEC layer and 
subsequent diffusion into the ECM.
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The main objective of this study was to determine the effect of MCP-1 local 
concentration on monocytes migration in the 3D tissue model and compare the outcomes to the 
traditional two-dimensional (2D) cell culture model results. We hypothesized that the MCP-1 
concentration gradient within the ECM of the 3D tissue model drives a different cellular response 
than that in the 2D model. 
This project was divided into three parts. The first part was to develop the 3D tissue 
model and to test the effect of the collagen matrix on endothelial cell behavior, by examining cell 
viability, permeability, CAMs/MCP-1 expression, and MCP-1 release under quiescent condition 
and when and when models were immunologically activated with tumor necrosis factor-α (TNF-
α). The second objective was to compare monocyte adhesion and transmigration across the 
endothelial layer between the 2D and 3D models, in order to study the effect of local 
concentration gradients on the monocytes migration process. The third part was to develop a 
mathematical model to characterize the MCP-1 concentration gradients in the collagen matrix of 
the 3D tissue model. The amount of MCP-1 released from the endothelial cells was used to derive 
a mathematical model to estimate the MCP-1 concentration within the 3D tissue model at various 
time points and locations within the matrix. 
 
Conclusions are summarized as follows: 
i. HAEC showed high cell viability in the novel 3D tissue models. Cell viability was not 
significantly different than HAEC grown in the 2D models, suggesting that existence of 
the collagen matrix beneath the endothelium did not change cells metabolic activity. 
ii. Growing HAEC on a collagen matrix altered formation of cell-cell junctions and HAEC 
spreading behavior according to HAEC surface area distribution analysis, which led to 
having a significant decrease in trans-endothelium electrical resistance of HAEC in the 
3D tissue models compared to the 2D models. 
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iii. HAEC in both models could be activated by an inflammatory stimuli. HAEC showed an 
increase in the level of VCAM-1 and ICAM-1 surface expression, when activated by 
TNF-α.  
iv. HAEC on the 2D models had significantly higher intensity of VCAM-1 and ICAM-1 
expression on the surface associated with monocytes migration than the HAEC from the 
3D tissue models after 24 h stimulation. 
v. HAEC showed high expression of PECAM-1 in both models before and after activation 
which indicates that TNF-α did not have a significant effect on the PECAM-1 expression 
of cell-cell boundaries.  
vi. MCP-1 expression on HAEC surface was upregulated with TNF-α activation at 6 h when 
it reached a plateau after that and remained unchanged up to 24 h stimulation for both 
models. HAEC had a similar MCP-1 expression time course in the 3D tissue models 
compared to the 2D models.  
vii. Activation of the HAEC resulted in an increase in MCP-1 production. The release of 
MCP-1 from the HAEC in the tissue models under normal and activated culture 
conditions was determined at various time points over a 24 h period. The MCP-1 release 
profile was used to derive the source term of MCP-1 production of the HAEC in the 
mathematical model.  
viii. MCP-1 concentration released from HAEC to the endothelium basal compartment after 
24 h stimulation is shown to be identical in the 2D and 3D models. However, in fact a 
significant difference in the net release of MCP-1 compared to the control was observed 
between the collagen matrix of the 3D tissue models and the HAEC basal layer in the 2D 
models. Accordingly, due to the sample concentrated in the collagen matrix, resulting in 
an abrogated release into the surrounding media, an earlier detection of MCP-1 release 
was expected from the 3D tissue models. As it was shown that there was no significant 
difference in the MCP-1 concentration released to the basal layer of HAEC in the 2D 
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models after 6 h activation compared to the control samples. However, stimulating the 
HAEC in the 3D tissue model for 6 h had a significant effect on MCP-1 release in the 
collagen matrix beneath the HAEC layer. 
ix. The formation of a haptotactic gradient drives an increase in the number of monocytes 
that migrate across the endothelial cell layer. Haptotactic gradients were only formed in 
the 3D tissue models and not the 2D models. There was a significant increase in the 
number of monocytes that migrated across the endothelial cell layer in the 3D tissue 
models compared to the 2D models.   
x. The rate expression for the binding reaction of MCP-1 to collagen was determined 
experimentally by measuring the initial rates of reaction for various MCP-1 
concentrations applied to a collagen matrix without cells.  
xi. An unsteady-state, one-dimensional transport equation used to describe MCP-1 transport 
in the 3D tissue model was solved in MS-Excel with VBA using the Crank-Nicolson 
numerical method.  
xii. The concentration gradient of MCP-1 (both free and bound) varied with position within 
the collagen matrix and increased over time in response to TNF-α activation. The 
concentration of bound MCP-1 surpasses the gradient of free MCP-1 after 12 h. 
xiii. The mathematical model was validated with the measured experimental data. The 
numerical results obtained from solving the differential mathematical equations were fed 
in MATLAB software and a curve fitting tool was applied to the data to determine the 
best curve fit for MCP-1 concentrations at different location within the collagen matrix 
and different stimulation time point. Obtained equation of MCP-1 concentration as a 
function of location and time was used to calculate the expected total MCP-1 mass in the 
collagen matrix at each time point. The mathematical model demonstrated a good 
prediction of total MCP-1 amount within the collagen matrix for the selected incubation 
time points with TNF-α.  
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 In conclusion, we have shown that kinetics and the level of CAMs expression on the 
cells surface and MCP-1 release in the 3D tissue model is different from the 2D model which had 
an effect on monocytes adhesion and transmigration through the endothelial layer between the 
two models. However, there is no significant difference in MCP-1 expression between two 
models. This 3D tissue model consisting of a collagen matrix would be a better alternative 
experimental model to mimic the subendothelial ECM. The added dimension is crucial for the 
creation of diffusive concentration gradients, which is an important factor in many physiological 
conditions. The concentration gradient formed in the 3D tissue model is distinctly different 
compared to the one in the 2D model, where the secreted factors from the endothelial cells 
dissolve quickly into the surrounding media. Many questions still remain about the mechanisms 
controlling monocytes transmigration from the blood flow to the infected tissue. With the 
completion of ongoing future phases, an advanced in vitro tissue model will be developed and can 
be used to study monocytes migration associated with diseases like atherosclerosis. 
 
Consequently, future work will be directed towards addressing the following points:  
1) Describe the mechanisms involved in MCP-1 and collagen binding. There is a large 
body of evidence that chemokines can bind with endothelial cell surface and ECM 
proteins, where the chemokines can be localized and immobilized, forming bound 
gradients. The binding is believed to be mediated by macromolecule polymers called 
glycosaminoglycans (GAGs) [44, 47, 69-75, 115]. GAGs on the cell surface and in the 
ECM can interact with chemokines [44, 47, 69, 70, 72, 75-81] and prevent chemokines 
from diffusing and being washed away by the blood shear flow [47, 74, 75, 82, 83]. The 
localized chemokine gradient can direct leukocytes from the blood flow to the 
subendothelial layer [72]. Several studies have investigated chemokine-GAG interactions 
in the ECM in vivo [71-74, 79, 83], but these interactions could not be assessed in an in 
vitro chemotaxis assay [72, 83, 87] due to the lack of the ECM to form the haptotactic 
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concentration gradient. GAGs can also interact with type I collagen [84, 85]; therefore, 
the binding reaction between MCP-1 and the collagen in this study can be mediated by 
GAGs, which are available from FCS in the cell growth media supplements [116]. 
Determining the role of GAGs in the proposed collagen/MCP-1 binding reaction will lead 
towards a better understanding of the underlying mechanisms in monocytes migration 
and atherosclerosis formation.  
2) Add fluid flow to the current models. In the current work, the systems were all at static 
conditions. Static systems were used in order to simplify the development of the 
experimental and mathematical models used to describe MCP-1 transport and monocytes 
migration. Static systems can also be used to study atherosclerosis, since lesions develop 
predominantly at sites exposed to low or disturbed blood flow, such as branches, bends, 
and bifurcations in the arterial tree. Proposed theories of atherosclerosis, such as the mass 
transport theory and the sheer stress theory, describe altered transport of bioactive 
substances and cells within areas of flow stagnation with low shear stress on the 
endothelium.  Such conditions can be represented in a static experimental system.  
However, an even better representation of in vivo conditions would be experimental and 
mathematical models that take the complex flow patterns into consideration. As the tools 
become available to create and analyze such complex models, the result may be an even 
better insight into the mechanisms driving monocytes migration in the early stages of 
atherosclerosis. 
3) Monocyte differentiation in the ECM. Atherosclerosis is initiated by endothelial 
dysfunction, inflammation, and extracellular matrix (ECM) remodeling [5, 6]. Plaque 
formation begins with a subendothelial accumulation of lipid substances, followed by the 
adhesion of monocytes and lymphocytes to endothelial cells and their subsequent 
migration across the endothelial layer to the ECM. Monocytes differentiate into 
macrophages and foam cells by consuming lipid substances and interacting with low 
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density lipoprotein (LDL) [7-13]. The foam cells produce and release inflammatory 
signals that cause recruitment of additional monocytes to the area, and the development 
of an atherosclerosis lesion [13]. The 3D tissue model introduced in this study can be 
utilized to investigate the differentiation of the monocytes that migrated to the 
subendothelial ECM into foam cells by including additional bioactive substances 
involved in atherosclerosis, such as LDL. The 3D tissue model would provide a way to 
study the transport and accumulation of LDL in the ECM and investigate the effect of 
LDL transport on monocyte differentiation. 
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